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Abstract 
 
Development of a 3D In Vitro Model of the Blood-Brain Barrier in Layered 
Microfluidic Devices 
by 
Jack D. Wang 
 
Chair: Mohamed E.H. ElSayed 
 
The endothelial cells lining the capillaries that supply the brain with oxygen and 
nutrients present a highly regulated transport barrier known as the blood-brain barrier 
(BBB). These endothelial cells are characterized by thick cell membranes, low number of 
endocytic vesicles, absence of fenestrae, and highly organized tight junctions that restrict 
molecular diffusion across the paracellular space. The integrity and function of the BBB is 
finely regulated by several environmental conditions including endothelial cell-to-cell 
contact, communication with other neural cells such as astrocytes and pericytes, and the 
local concentration of secreted chemical factors. Several groups have cultured primary and 
immortalized brain capillary endothelial cells to develop an in vitro model that mimics the 
BBB for the purpose of screening transport properties of new drug molecules designed for 
treatment of central nervous system (CNS) disorders. However, these in vitro models 
ix 
generally failed to mimic the restrictive transport properties of the BBB due to the 
formation of “loose” tight junctions, lower expression of specific carriers, or limited cell 
viability. We developed a 3D in vitro model of the BBB by culturing brain endothelial cells 
with pericytes and astrocytes in layered microfluidic channels. We hypothesized that the 
proposed model would improve endothelial cell polarization and enhance the formation of 
tight junctions, provide better endothelial cell-to-cell contact that is important for barrier 
development, and prevent the dilution of secreted neurotrophic factors, and these conditions 
collectively led to the development of an in vitro model that can truly mimic the BBB. 
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Chapter 1 
 
Introduction 
 
 
1.1 What is the Blood-Brain Barrier? 
The endothelial cells lining the capillaries that supply the brain with oxygen and 
nutrients present a highly regulated transport barrier known as the blood-brain barrier 
(BBB). These endothelial cells are characterized by thick cell membranes, low number of 
endocytic vesicles, absence of fenestrae, and highly organized tight junctions that restrict 
molecular diffusion across the paracellular space [1-4]. The integrity and function of the 
BBB is regulated by several environmental conditions including endothelial cell-to-cell 
contact [4], communication with other supporting cell types such as astrocytes [5, 6] and 
pericytes [7-9], and the local concentration of secreted neurotrophic factors [6]. Due to the 
presence of this highly functional barrier, only 2% of small-molecule drugs (< 500 Daltons) 
can across the BBB to achieve their effective concentrations and nearly none of the existing 
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large-molecule drugs can across the BBB [10]. Only a few central nervous system (CNS) 
disorders, such as depression, epilepsy, chronic pain, and affective disorders, respond to 
clinical treatments by the 2% of small-molecule drugs that we have; on the other hand, 
many more serious CNS disorders cannot be effectively treated by these small therapeutic 
molecules including Alzheimer disease, Huntington disease, stroke, brain cancer, brain and 
spinal cord injury, HIV infection of the brain, etc [10]. Because of limitations of the 
currently available drug molecules, the CNS pharmaceutics market needs to grow more 
than 500% to reach the cardiovascular drug market despite the fact that there are 4 times 
more people afflicted with CNS disorders than cardiovascular disorders [11]. 
  
1.2 Transport of the Blood-Brain Barrier 
Early studies using electron microscopy combined with tracers demonstrated that 
there are several important differences between brain endothelial cells and their peripheral 
counterparts [12]. First, they exhibit very few endocytotic vesicles which reduce the ability 
of hydrophobic molecules to transport across the endothelial cells from blood into the brain; 
this is called transcellular transport and it is very limited in the BBB [1]. Free membrane 
diffusion only applies to small hydrophobic molecules such as ethanol [4]. Essential 
nutrients are transported through carrier-mediated transporters; for example, GLUT-1 is 
responsible for the transport of glucose from the blood side to the brain. Other examples 
include monocarboxylic acid transporter MCT1, large neutral amino-acid transporter LAT1, 
and sodium-coupled nucleoside transporter CNT2 [4].  
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Second, intercellular junctions, specifically the tight junctions, formed between 
adjacent endothelial cells in the brain severely restrict the transport of hydrophilic 
molecules, which we call paracellular transport. Brain endothelial tight junctions are 
formed with occludin and a family of claudins such as claudin-1 and claudin-5; these 
protein strands are then connected to the cells through zonula occludens proteins [13]. It is 
worth noting that the changes of expression level of a certain tight junction protein do not 
always reflect changes in the transport properties through the paracellular route [4]. 
However, changes in the structure of these tight junction proteins can affect BBB function. 
For example, erroneous distribution of tight junction proteins in the internal and external 
membrane of brain endothelial cells will result in altered polarity of glucose transporter 
GLUT-1 resulting in stroke-prone spontaneously hypertensive conditions with no changes 
in occludin, claudin-1, clduain-5 and zonula occludens protein-1 expression [4].  
Finally, efflux transporters such as the P-glycoproteins are expressed in the BBB 
and have been studied extensively [14, 15]. It has been found that this particular transporter 
possesses broad specificity and is able to recognize hundreds of compounds ranging from 
330 daltons up to 4000 daltons in size [16]. Its primary function is to capture diffusing 
molecules transcellularly from the blood side to the brain tissue and pump them back to the 
blood side against their concentration gradients at the expense of ATP. The existence of P-
glycoproteins, even though are essential to keep the brain tissue from contacting potential 
toxins, they are detrimental to the delivery of therapeutic agents to the brain. One such 
example is the treatment of brain tumor. Chemotherapeutic agents such as paclitaxel and 
doxorubicin have been determined to be substrates of the P-glycoprotein [17, 18]. As a 
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result, even though improved cancer therapeutics have been able to prolong the survival of 
patients with systemic cancer, the incidence of brain metastatic disease is increasing [15]. 
Furthermore, due to the restrictive transport of chemotherapeutic agents resulting in 
minimal drug concentration in the brain and the intrinsic resistance to chemotherapies of 
primary brain malignancies, there are currently very limited options for effective drug 
delivery into the brain for treatment of brain tumor [15]. 
 
1.3 Alternative Drug Delivery Methods to the BBB 
The inability of conventional drug molecules to across the BBB has, in some cases, 
forced drug development programs to go forward without the consideration of BBB 
transport at all [10]. This led to the development of craniotomy-based drug delivery method 
where a hole is drilled in the head, and drugs are directly administered to the brain, thus 
bypassing the BBB altogether. However, drug molecules administered this way tend to stay 
at the injection site and cannot effectively penetrate the brain parenchyma. With such 
limited penetration capability, only 1% of the brain volume is reached, making this method 
ineffective against most, if not all, brain diseases. 
Clinical research has also shown that osmotic modification of the BBB can increase 
the delivery of drug molecules, specifically chemotherapeutic agents for the treatment of 
brain tumors. Typically 1.4 M mannitol solution is introduced into the system by 
intracarotid infusion resulting in the opening of tight junctions at the BBB due to increased 
osmotic pressure at the apical side of the capillaries [19]. This method, coupled with 
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intravenous infusion of chemotherapeutic agents, has been found to prolong survival of 
patients with high-grade gliomas by 10-12 months [19]; however, this therapeutic method 
is associated with cognitive deterioration or changes in the central nervous system (CNS) 
detectable by Magnetic Resonance Imaging [20]. 
In comparison to the limitations of methods such as the craniotomy-based drug 
delivery system and osmotic modification of the BBB, if drug molecules administered 
intravenously or intracarotidly are capable of taking advantage of the transport systems, 
they have the potential to become much more effective at penetrating the BBB while 
minimizing side effects at the same time. Drug molecules capable of such maneuvers have 
the ability to reach nearly all of the neurons in the brain since every neuron is supported by 
its own capillary vessel [10]; however, it requires innovative drug-targeting systems that 
have the capability of traversing through the BBB. Development of such system cannot 
begin until detailed molecular and cellular biology of the BBB are revealed; and obtaining 
such information requires an accurate and cost-effective in vitro BBB model that can be 
used repeatedly for drug screening and experimentation. 
 
1.4 Current In Vitro Blood-Brain Barrier Models 
 Since BBB is a transport barrier that has the capability to even restrict the 
movement of ions, the simplest form of measuring paracellular transport “tightness” is to 
assess the trans-endothelial electrical resistance [4]. While the earliest measurements on 
cultured monolayers of brain endothelial cells were published in 1987 by using Ussing 
chamber [21, 22], the methodology has become much easier since then through the widely 
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available semi-porous membrane inserts and the “chopstick” electrodes acting as Volt-Ohm 
resistance meters. These laboratory equipments allow repeated and rapid measurements of 
TEER. TEER is calculated as resistance measured (Ώ) multiplied by the area of endothelial 
monolayer (cm2) [4]. Another important measurement for evaluating paracellular transport 
is permeability using a fluorescently labeled or radioactive hydrophilic molecule [4]. A 
typically permeability value is evaluated by putting the marker molecule in the apical side 
of the endothelial monolayer and let it diffuse as a function of time. At the end of the time 
period, permeability is calculated by using the concentrations, volumes, surface area, and 
duration. It has a unit of cm/s. 
 Realizing the importance of in vitro BBB models, many groups have attempted to 
construct such model using both primary and immortalized cell lines. Primary endothelial 
cells isolated from bovine, human, porcine, and rodent are typically used in modeling the 
BBB [4]. Among all such established models, one porcine model demonstrated relatively 
high TEER and low permeability [4], which are key characteristics of the BBB. Despite the 
ethical questions and the logistical difficulties of obtaining human brain tissue, there have 
been reports of established human BBB models; these models, however, are less robust 
than porcine models according to published data [4]. All primary models suffer from 
several disadvantages. Primary cells are expensive to obtain and the reconstitution process 
is time consuming. Furthermore, the homogeneity of obtained cells is difficult to determine, 
and can be easily contaminated with neighboring cell types such as the pericytes [4]. 
 In recent years, immortalized brain endothelial cell lines have been more commonly 
used than primary cell lines due to their ease of manipulation and reproducibility. There are 
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currently more than 20 endothelial cell lines available and virtually all of them have been 
used to establish in vitro BBB models with published results [4]. Many of these models 
utilize transwell system, which is the standard tool for in vitro drug screening. The major 
issue that such models suffer is leaky monolayer formation which results in low TEER and 
high permeability values. Since these models did not generate BBB characteristics, it is 
very difficult to use them for BBB related studies. We believe that the reasons for the failed 
mimicry of the restrictive transport properties of the BBB can be due to the formation of 
“loose” tight junctions between adjacent endothelial cells, lower expressions of specific 
carriers, or limited cell viability. This can be attributed to the lack of proper micro-
environments and efficient integration of endothelial and neural cells in a model that allow 
cell-to-cell communication necessary to induce the proper differentiation of brain capillary 
endothelial cells, formation of restrictive tight junctions, and functional expression of 
different transporters at the levels present in vivo. 
 In 2008, Cucullo and colleagues published a dynamic in vitro model of the BBB 
that utilizes astrocyte co-culture and pulsatile flow, both of which are key environmental 
factors that influence the development and regulation of BBB [23]. The model 
demonstrated high TEER values similar to that of primary porcine endothelial cell culture 
model and low permeability measured by using paracellular transport markers such as 
mannitol and sucrose. Curiously, co-culture of endothelial cells with astrocytes was not 
required to obtain BBB-like characteristics in this model [23]. While technical difficulties 
involved with the model set-up, such as the handling and cost of the hollow fibers used for 
cell seeding and flow parameters that are inconsistent with in vivo capillary conditions, do 
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exist, the model itself proved that micro-environments are the most important factors that 
dictate the proliferation and differentiation of endothelial cells. Therefore, in order to 
develop an accurate in vitro model of the BBB focus should be set upon recreating the 
micro-environments of brain endothelial cells instead of manipulating innate cellular 
properties. 
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Chapter 2 
 
Background 
 
 
2.1 Rationale for Using PDMS Microfluidic Channels for In Vitro Modeling 
 Microfluidic channels have been used in many biological applications including 
rapid high density sequencing [24-26], polymerase chain reaction [27-31], and detection of 
single molecules [32-34] since its development in the 1990s. They have been particularly 
useful in the development of biological assays such as particle immunoassays [35], cell-
based high throughput screening for drug discovery [36], and capacitance cytometry of 
single eukaryotic cells [37]. The micron-scale size of these microfluidic devices offers 
many unique advantages including close mimicry of many in vivo microenvironments [38] 
and small volume requirement compared to conventional analysis systems [39]. 
13 
 Several materials have been used to fabricate these microfluidic channels such as 
silicon, ceramic , quartz glass, polymethyl methacrylate, SU-8, and poly(dimethylsiloxane) 
(PDMS) [30, 35, 36, 39-41]. The optical clarity [42], biocompatibility [43], and high 
oxygen diffusivity of PDMS [44] render it the most commonly used material in fabrication 
of microfluidic channels for biological applications. Several groups have capitalized on 
these advantages and used PDMS-based microfluidic channels to develop in vitro models 
of different physiological processes. For example, Sodunke et al. successfully conducted a 
study on the replication of hepatitis B virus in normal human hepatocytes using a PDMS-
based microfluidic platform [45]. PDMS-based microfluidic channels also proved efficient 
in maintaining high and low density cultures of mammalian neuronal cells [46]. Recently, 
Huh et al. demonstrated the versatility of PDMS-based channels by creating a microfluidic 
airway system that simulates human airway epithelia and physiological airway flow found 
in the respiratory system [47]. 
 One key limitation of these channels is the hydrophobicity of the PDMS surface, 
which reduces its wettability by aqueous biological fluids and affects its compatibility with 
cell culture. Plasma oxidation has been routinely used to introduce silanol groups on the 
PDMS surface to become more hydrophilic and fitting for in vitro cell culture [48]. 
However, diffusion of free uncross-linked PDMS chains from the bulk plymer to the 
channel surface diminishes its hydrophilic character causing the channel wall to gradually 
revert to its intrinsic hydrophobic nature [49]. Furthermore, exposure of oxidized PDMS 
surfaces to air for an extended period of time restores its hydrophobic character. Extraction 
of PDMS surfaces using different solvents to remove unreacted oligomers followed by 
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plasma oxidation was shown to increase the stability of hydrophilic PDMS surfaces by 7 
days. Combination of plasma oxidation followed by treatment with SiCl4 and CCl4 gases or 
deposition of metal oxides have also been used to increase the stability of hydrophilic 
PDMS surfaces. Despite the promise of these approaches in maintaining the hydrophilic 
nature of oxidized PDMS surfaces, they are not routinely used in fabrication of PDMS 
devices particularly those developed for biological assays. An earlier study confirmed the 
hydrophobicity of PDMS devices when Nile Red (a hydrophobic fluorescent dye) diffused 
into the PDMS wall of microfluidic channels shown by the retention of the fluorescence 
signal after repeated washes. While this earlier study by Toepke et al. provides a visual 
evidence of molecular absorption into PDMS channels, it does not provide any quantitative 
methods to predict the absorption of other hydrophobic molecules into PDMS microfluidic 
channels. It is essential that we can understand how molecules interact with the PDMS 
walls before any quantitative assays are used in PDMS microfluidic channels. 
 
2.2 Design of PDMS Microfluidic Channels for Modeling the Blood-Brain Barrier 
 The design of our microfluidic device incorporates two layered microfluidic 
channels that sandwich a polyester membrane (0.4µm pore size) along the entire length of 
the channel, which was used to culture b.End3 cells (Figure 2.1). The device is designed to 
incorporate a cross section between the top and bottom channels sufficient to allow 
measurement of solute’s permeability across b.End3 cell monolayers while maintaining an 
elongated geometric shape and scaled down dimensions. The elongated rectangular shaped 
channel serve to guide endothelial cell growth, which has been shown to enhance 
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 The microfluidic devices used for culture of b.End3 cells are composed of layered 
microfluidic channels sandwiching a porous membrane (0.4µm pore size), which were 
fabricated using soft lithography following established protocols [41, 51]. Briefly, PDMS 
prepolymer was mixed with the curing agent at a 10 (prepolymer)/1 (curing agent) weight 
ratio before casting onto two 4 inch silicon wafers containing a 200μm thick positive relief 
pattern. The mixture was cured at 60°C for 2 hours before peeling the PDMS layer off the 
silicon wafer. Access holes were punched with a 16 gauge blunt syringe (1.65 mm outer 
diameter) forming the inlet and outlet holes for each channel. We spun coated a 
PDMS/toluene mixture prepared at a 3/2 weight ratio on a clean glass slide for 1 minute to 
generate a thin mortar layer, which was used to glue the top and bottom PDMS layers. 
Ag/AgCl recording electrodes were embedded in 500μm x 500μm side channels when 
fabricating microfluidic devices for measurement of transendothelial electrical resistance 
(TEER) across b.End3 monolayers following a published procedure [51]. Polyester 
membranes with an average pore size of 0.4µm were sandwiched between the aligned top 
and bottom PDMS layers and glued together before curing for 1 hour until the PDMS 
mortar completely hardened. Pipette tips (100μl) were inserted into the inlets and outlets of 
the top and bottom channels to serve as medium reservoirs before exposure to plasma 
oxygen for 5 minutes. Sterile fibronectin solution (25μg/ml) was loaded into the top PDMS 
channel for 24 hours to coat the polyester membrane followed by exposure of the 
microfluidic device to UV radiation for sterilization before seeding of b.End3 cells. 
TEER values across b.End3 monolayers cultured in layered microfluidic channels 
was measured on daily basis following our published protocol [51]. Briefly, impedance 
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spectra were taken using an Autolab potentiostat/galvanostat at 0.1V of alternating current 
passing between the two embedded electrodes within layered microfluidic channels. 
Frequency range between 10Hz to 1.00MHz was used to yield a total of 64 impedance 
measurements. The control impedance spectra measured before seeding the cells were 
subtracted from the measured impedance spectra with b.End3 cells to eliminate their 
contribution to the calculated resistance. We developed a MATLAB code (The MathWorks 
Inc., Natick, MA) using its optimization toolbox to resolve the TEER values, which were 
normalized to the surface area of the cell monolayers to calculate the resistance in Ω.cm2. 
 
2.3 Single Culture of Brain Microvascular Endothelial Cells in Layered PDMS 
Microfluidic Channels 
Stewart and co-workers provided one of the earlier examples showing the effect of 
microenvironment on the barrier properties of chick capillaries implanted in quail brain and 
quail somite grafts [52]. They showed that chick capillaries implanted in quail brain graft 
displayed blood-brain barrier like properties while those implanted in quail somite graft 
near the skeletal muscle did not exhibit the same restrictive properties [52]. In this research, 
we aimed to mimic the shape and dimensions of small blood vessels in the design of our 
layered microfluidic channels, which will allow better cell-to-cell contact, increase the 
surface-to-volume ratio, minimize the dilution of secreted factors, and reduce the needed 
volume to evaluate the transport of different markers [41, 50, 53-55]. We can achieve this 
goal by adjusting the dimensions of the top channel to resemble a blood capillary while 
maintaining a large aspect ratio and a small total volume (17 µl). Starting with 2mm-wide 
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channels, it can be hypothesized that channel width and geometry can enhance b.End3 cell-
to-cell contact and guide their alignment along the longitudinal axis of the channel, which 
is supported by previous reports utilizing microfluidic devices with similar width and 
height [56]. Renkin function, a frequently used mathematical model that can resolve the 
radius of the tight junctional pores in both endothelial and epithelial monolayers, can help 
demonstrate and verify that b.End3 cells cultured in PDMS microfluidic channels can 
indeed form “tighter” and more “restrictive” tight junctions in the radius of the intercellular 
space. We hope that by developing an in vitro model of the BBB where barrier integrity is 
enhanced by controlling the dimensions of the microfluidic channel without the need for 
flow-mediated shear stress, we can take a significant step towards the development of 
simplified yet robust in vitro models. 
Previous works have indicated that geometry of the cell culture micro-environment 
not only can help define vascular architectures [57] and cell adhesion [58], it can also 
influence cell growth, differentiation, and apoptosis [50]. Therefore we hypothesized early 
on that the small width of the channels can induce better cell-to-cell contact and play an 
important role in assisting the formation of tight junctions. This effect can be demonstrated 
by increasing the width of the microfluidic channels from 2 mm to 4 and 8 mm. We will 
then evaluate TEER measurements and permeability values of marker molecules to confirm 
the effect of geometry has on endothelial monolayers. 
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2.4 Bi- and Tri-Culture Configurations in Layered PDMS Microfluidic Channels 
 It has long been acknowledged that both pericytes [24] and astrocytes [6] play very 
important roles in the differentiation and development of brain endothelial cells. Pericytes, 
in particular, partially surround the brain capillaries at endothelial tight junctions, and are 
usually found between endothelial cells and astrocyte end-feet. This strategic position 
allows pericytes to interact with both the endothelial cells and the astrocytes [8, 59]. 
Previous researches have suggested that pericytes, based on their morphology and 
localization, play important roles in endothelial cell function and modulation of blood flow, 
and they make direct contact with endothelial cells through gap and adherens junctions [7, 
59, 60]. It is also important to note that at the BBB the ratio of pericytes to endothelial is 
one of the highest in any organ [61]. Furthermore, there are evidences in the literature that 
suggest pericytes are capable of secreting signaling molecules that are essential to the 
differentiation and contractile properties of endothelial cells [9, 62, 63]. Astrocytes, too, 
have been found to secrete a range of neurotrophic factors such as transforming growth 
factor-β (TGFβ) [6], glial-derived neurotrophic factor (GDNF) [64], and basic fibroblast 
growth factor (bFGF) [6]. It has been found that these factors can induce many aspects of 
the BBB phenotype in endothelial cells in vitro [2, 6, 10]. At the same time, endothelial-
derived factor such as leukaemia inhibitory factor (LIF) has been documented to induce the 
differentiation of astrocytes [65]. The cross-interaction between endothelial cells and 
astrocytes are mutually beneficial and ensures the differentiation of both BBB and 
astrocytic development. 
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 Based on the importance of pericytes and astrocytes on endothelial differentiation, 
we want to design our bi- and tri-culture configurations to examine the feasibility of 
culturing b.End3 cells together with pericytes and astrocytes and whether these co-culture 
configurations can induce BBB-like transport properties. For our bi-culture configuration, 
our goal will be to mimic the close promixity of endothelial cells and the pericytes; 
therefore we will culture pericytes on the back-side of the semi-porous membrane, where 
the endothelial cells are growing on, in the microfluidic devices. This configuration ensures 
that b.End3 cells and pericytes are in close contact with each other in the condition that is 
similar to the conditions in vivo. For our tri-culture configuration, we will add astrocytes to 
the bottom layer of the channels. While the astrocytes are not in direct contact with the 
endothelial-pericyte layers, the secreted neurotrophic factors that are so critical to the BBB 
development still reaches the b.End3 cells through diffusion; again, creating a similar 
condition to the in vivo conditions. To further validate the effects of astrocytes on 
endothelial-pericyte layers, we will modify our original device and change the height of the 
bottom channel from 0.2mm to 0.6mm and 1mm. The purpose of modifying the bottom 
channel is to increase the distance between the astrocytes and the endothelial-pericyte 
layers and increase the volume of the bottom channel in order to subject the secreted 
neurotrophic factors to dilution. 
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Chapter 3 
 
 
Quantitative Analysis of Molecular Absorption into PDMS Microfluidic Channels 
 
 
3.1 INTRODUCTION 
 Microfluidic channels have been used in many biological applications including 
rapid high density sequencing,[1-3] polymerase chain reaction,[4-8] and detection of single 
molecules[9-11] since its development in the 1990s. They have been particularly useful in 
the development of biological assays such as particle immunoassays,[12] cell-based high 
throughput screening for drug discovery,[13] and capacitance cytometry of single 
eukaryotic cells.[14] The micron-scale size of these microfluidic devices offers many 
unique advantages including close mimicry of many in vivo microenvironments[15, 16] and 
small volume requirement[17, 18] compared to conventional analysis systems. 
 Several materials have been used to fabricate these microfluidic channels such as 
silicon,[19-21] ceramic,[22] quartz glass,[23-26] polymethyl methacrylate,[27, 28] SU-
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8,[29] and poly(dimethylsiloxane; PDMS).[30, 31] The optical clarity,[32] 
biocompatibility,[33] and high oxygen diffusivity[34] of PDMS render it the most 
commonly used material in fabrication of microfluidic channels for biological applications. 
Several groups have capitalized on these advantages and used PDMS-based microfluidic 
channels to develop in vitro models of different physiological processes. For example, 
Sodunke et al successfully conducted a study on the replication of hepatitis B virus in 
normal human hepatocytes using a PDMS-based microfluidic platform.[35] PDMS-based 
microfluidic channels also proved efficient in maintaining high and low density cultures of 
mammalian neuronal cells.[36] Recently, Huh et al demonstrated the versatility of PDMS-
based channels by creating a microfluidic airway system that simulates human airway 
epithelia and physiological airway flow found in the respiratory system.[37] 
 One key limitation of these channels is the hydrophobicity of the PDMS surface, 
which reduces its wettability by aqueous biological fluids and affects its compatibility with 
cell culture.[31] Plasma oxidation has been routinely used to introduce silanol groups on 
the PDMS surface to become more hydrophilic and fitting for in vitro cell culture.[31] 
However, diffusion of free uncross-linked PDMS chains from the bulk polymer to the 
channel surface diminishes its hydrophilic character causing the channel wall to gradually 
revert to its intrinsic hydrophobic nature.[38] Furthermore, exposure of oxidized PDMS 
surfaces to air for an extended period of time restores its hydrophobic character.[31] 
Extraction of PDMS surfaces using different solvents to remove unreacted oligomers 
followed by plasma oxidation was shown to increase the stability of hydrophilic PDMS 
surfaces by seven days.[39] Combination of plasma oxidation followed by treatment with 
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SiCl4 and CCl4 gases[40] or deposition of metal oxides[41] have also been used to increase 
the stability of hydrophilic PDMS surfaces. Despite the promise of these approaches in 
maintaining the hydrophilic nature of oxidized PDMS surfaces, they are not routinely used 
in fabrication of PDMS devices particularly those developed for biological assays. An 
earlier study confirmed the hydrophobicity of PDMS devices when Nile Red (a 
hydrophobic fluorescent dye) diffused into the PDMS wall of microfluidic channels shown 
by the retention of the fluorescence signal after repeated washes.[42] While this earlier 
study by Toepke et al. provides a visual evidence of molecular absorption into PDMS 
channels, it does not provide any quantitative methods to predict the absorption of other 
hydrophobic molecules into PDMS microfluidic channels. 
 In this report, we provide a quantitative correlation between the partition coefficient 
(log P) of a series of marker molecules and their absorption into microfluidic PDMS 
channels at pH 7.0 as a function of solution temperature (25 ºC and 37 ºC) and incubation 
time (0.5, 1, 2.5, and 4.5 hours). The partition coefficient, log P, of a given molecule 
depends on its chemical structure and the associated hydrophilic/hydrophobic balance.[43] 
Log P is experimentally determined by the ratio between molecule’s concentration in a 
hydrophobic solvent (octanol) and concentration in a hydrophilic solvent (water) upon 
dissolution and reaching equilibrium in this biphasic solvent system as shown in equation 
1.[43] 
log P ൌ log ሾୱ୭୪୳୲ୣ	୧୬	୭ୡ୲ୟ୬୭୪ሿሾୱ୭୪୳୲ୣ	୧୬	୵ୟ୲ୣ୰ሿ  -----------------------------------------------------------------------Eq 1 
Molecules with high log P value such as Nile Red (log P = 5.0)[44] are highly hydrophobic 
and can easily partition into lipid bilayers[45] and absorb into hydrophobic PDMS 
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surfaces.[42] However, the majority of pharmaceutical and diagnostic agents have 
significantly lower log P values than 5 to achieve aqueous solubility and absorption from 
the gastrointestinal tract.[46] Consequently, there is a need to establish a relationship 
between log P of model solute molecules and their absorption into PDMS to predict the 
effect of molecular absorption of different therapeutic or diagnostic molecules on the 
accuracy and reproducibility of in vitro assays performed in microfluidic PDMS devices. 
 We selected five molecules with log P values that span the established log P range 
of current pharmaceutical agents[46, 47] and are commonly used as markers to assess the 
viability and barrier properties of epithelial and endothelial monolayers (Figure 3.1). 
 
 
Figure 3.1: Chemical structure and log P values of the selected marker molecules. 
 
Mannitol is a hydrophilic small molecular weight molecule with six hydroxyl groups and a 
log P value of -3.10.[48] Mannitol permeates across epithelial and endothelial barriers 
through the aqueous pores in the tight junction complexes and is routinely used as a 
paracellular permeability marker.[49] Dexamethasone is a glucocorticoid with a potent 
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anti-inflammatory effect.[50] Phenytoin is an anti-epileptic drug that is used to suppress 
abnormal brain activity including epileptic seizures.[51] Dexamethasone and phenytoin are 
moderately hydrophobic drug molecules with log P values of 1.83 and 2.47, 
respectively.[52, 53] Both dexamethasone and phenytoin are substrates for the P-
glycoprotein (P-gp) efflux pump present on the luminal side of intestinal epithelial cells, 
vascular endothelial cells, and cancer cells.[54-56] Both molecules are routinely used to 
assess the functional expression of the P-gp efflux pump in epithelial and endothelial 
monolayers used as in vitro screening tools.[54, 55] Rhodamine 6G is a hydrophobic, 
membrane-permeable, fluorescent dye with a log P of 2.62 that has been used to evaluate 
membrane potential based on its fluorescence intensity.[57] Diazepam is a hydrophobic 
drug molecule with log P of 2.8,[58] which allows it to freely diffuse across the cell 
membrane and is consequently used as a marker of transcellular permeability across 
epithelial and endothelial cell monolayers.[59] Diazepam is routinely used as a sedative, 
anticonvulsant, anxiolytic, and skeletal muscle relaxant.[60] These molecules were selected 
to span the log P range of major pharmaceutical agents (log P ~ 2.43).[47] Furthermore, we 
evaluated the effect of TiO2[61] and glass[62] coatings on the absorption of hydrophobic 
molecules into PDMS channels. 
 
3.2 MATERIALS AND METHODS 
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3.2.1 Materials 
Poly(dimethylsiloxane) (Sylgard 184) was purchased from Dow Corning (Midland, 
MI). SU-850 was purchased from MicroChem (Newton, MA). Titanium (IV) isopropoxide, 
Tetraethyl orthosilicate (TEOS), and Methyltriethyoxysilane (MTES) were purchased from 
Sigma Aldrich (St. Louis, MO). [14C]-D-Mannitol (100 μCi/ml) and [3H]-Phenytoin (1 
mCi/ml) were purchased from Moravek Biochemicals and Radiochemicals (Brea, CA). 
[3H]-Diazepam (1 mCi/ml) and [3H]-Dexamethasone (1 mCi/ml) were purchased from 
American Radiolabeled Chemicals, Inc. (St. Louis, MO). Rhodamine 6G was purchased 
from Invitrogen (Carlsbad, CA). All chemicals were used as delivered without further 
purification. 
 
3.2.2 Design and Fabrication of Microfluidic Channels 
 Microfluidic channels were fabricated using soft lithography following established 
procedures.[63] Briefly, PDMS prepolymer was mixed with the curing agent at a weight 
ratio of 10 (prepolymer):1 (curing agent) and was cast onto a 4 inches silicon wafer 
containing a 200 μm thick positive relief pattern. A single wafer was patterned to contain 5 
evenly spaced microfluidic channels where each channel is 40 mm x 2 mm x 200 µm (L x 
W x H) (Figure 3.2).  
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followed by washing the channel with 15 μl of fresh PBS for 12 consecutive times at 
different time points and immediately analyzed using liquid scintillation counting 
(Beckman LS 6500, Beckman Coulter Inc., Brea, CA) for radiolabeled markers or the 
Fluoroskan Ascent FL plate reader (Thermo Fisher Scientific Inc., Waltham, MA) for 
Rhodamine 6G. The amount of each marker present in the collected washes was normalized 
to that initially loaded into each channel to determine % absorption of different markers. 
Absorption rate (%/min/cm2) of each molecule was calculated by normalizing the % 
absorbed to the incubation time and channel surface area. 
 
3.2.4 TiO2 and Glass Coating of PDMS Channels 
TiO2 coating of PDMS channels was done following established protocols.[61] 
Briefly, PDMS microfluidic channels were filled with 2-propanol by applying a negative 
pressure of approximately 50 kPa at one end of the reservoirs while the remaining one was 
filled with 2-propanol. A mixture of 1:1 v/v of Titanium (IV) isopropoxide and 2-proponal 
was prepared and pumped through the channel for 1 minute to replace the loaded 2-
propanol. The reservoirs were then allowed to dry in order to properly apply the TiO2 
coating to the surface of PDMS channels. 
 For glass coating, water (adjusted to pH 4.5 with HCl), TEOS, MTES, and ethanol 
were mixed at a 1:1:1:1 v/v to prepare the pre-conversion sol mixture following published 
procedures.[62] This solution was heated in a microwave oven for 15 seconds before 
incubating at 65 °C for 12 hours. Channels were oxidized by oxygen plasma for 5 minutes 
to generate hydroxyl groups on the PDMS surface to allow covalent coupling between 
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PDMS and siloxanes. The channels were immediately filled with pre-converted sol mixture 
and placed on a hot plate at 100 °C for approximately 1 minute to coat the channel surface. 
The sol solution was removed from the channel using a vacuum pump leaving the desired 
glass coating on the PDMS surface. 
 
3.3 RESULTS AND DISCUSSION 
 
3.3.1 Absorption of Mannitol in PDMS Microfluidic Channels 
 All channels used in the absorption experiments were fabricated using the same 
master. Channels were used 30-60 minutes after their plasma oxidation and they were 
easily loaded with PBS solution and remained intact throughout the absorption experiments. 
Channel consistency is maintained by using the same amount of PDMS for fabrication (50 
g of PDMS prepolymer for 5 channels). All channels are then baked in the oven using the 
same master. Channel quality is checked by loading PBS solution and examined under the 
microscope at 10x magnification to confirm the absence of air bubbles. Microfluidic 
channels trapping any bubbles were immediately discarded. 
 Mannitol absorption into PDMS channels varied based on the incubation 
temperature and time (Figure 3.3). The total amount of [14C]-mannitol retrieved from each 
channel in the initial collection (IC) and subsequent washes with fresh PBS were 
normalized to the amount of [14C]-mannitol loaded into the same channel and the 
difference represents the % of mannitol molecules absorbed into the PDMS surface (Figure 
3.3). Results show that 66%-82% of the loaded mannitol was retrieved after incubation for 
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0.5-4.5 hours in PDMS microfluidic channels at 25 °C (Figure 3.3A). In comparison, 92% 
- 100% of the loaded mannitol was retrieved after incubation in similar microfluidic 
channels at 37 °C for the same incubation periods (Figure 3.3B). Results show similar 
percentages of mannitol retrieval from PDMS channels at all incubation times regardless of 
the solution temperature (Figure 3.3A & 3.3B). However, results show higher percentages 
of mannitol retrieval upon incubation at 37 °C compared to that observed at 25 °C, which is 
attributed to the formation of hydrogen bonds between the silanol’s OH groups displayed 
on the surface of oxidized PDMS and the six hydroxyl groups of mannitol molecules at 
lower temperature. Elevating solution temperature from 25 °C to 37 °C provides sufficient 
energy to break the hydrogen bonds and increase mannitol retrieval at different time points 
(Figure 3.3B). 
 We calculated the increase in solution energy due to temperature increase from 
25 °C to 37 °C using the following heat capacity equation: 
Q ൌ	׬ Cp	dT ൌ Cp ൈ ሺT2 െ T1ሻ୘ଶ୘ଵ --------------------------------------------------------------Eq 2 
where Q is the thermal energy resulting from the temperature difference, T2 is the elevated 
temperature (37 °C), T1 is the standard room temperature (25 °C), and Cp is the specific 
heat capacity for the mannitol solution, which is assumed to be equal to water (4.18 Jg-1K-1) 
given that mannitol was dissolved in PBS. The calculated thermal energy as a result of 
temperature difference is 50.18 Jg-1. 
 Using the heat calculated in equation 2, we calculated the energy available from the 
elevated temperature to mannitol molecules (15 µl with density similar to water) loaded in 
the microfluidic channels using equation 3. 
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E୲ ൌ Q ൈ m -----------------------------------------------------------------------------------------Eq 3 
Where Et is the available energy and m is the mass of the mannitol solution. Based on 
equation 2, increasing the solution temperature from 25 °C to 37 °C provides 0.75 J of 
additional energy (Et) to the loaded mannitol solution. 
 Earlier research showed that (O — H - - - O) hydrogen bond has 21 kJ.mol-1 and 
requires a dissociation energy of 3.49×10-20 J.[64, 65] Based on the specific activity of 
[14C]-D-Mannitol (100 μCi/ml; 60×103 uCi/mmol), the number of mannitol molecules 
loaded in each microfluidic channel is 3.01×1015 molecules. These molecules will form 
2.05×1016 hydrogen bonds and require 0.72×10-3 J to dissociate assuming that each of the 
OH groups of loaded mannitol molecules formed a hydrogen bond with a silanol group on 
the PDMS surface. Earlier calculations show that increasing the solution temperature from 
25 °C to 37 °C provides 0.75 J, which is 1000-fold higher than the energy required to break 
the maximum number of hydrogen bonds formed between the loaded mannitol molecules 
and the OH groups displayed on the PDMS surface. 
 Absorption of mannitol and other molecules depend on the incubation time and the 
total surface area of PDMS microfluidic channels. Consequently, we normalized the 
percentage of absorbed molecules to the incubation period (minutes) and the PDMS surface 
area (cm2) to calculate the absorption rate (%/min/cm2) of different markers to extrapolate 
these findings to other microfluidic devices with different architectures and geometry. 
Results show that the absorption rate of mannitol dropped with the increase in incubation 
time and regardless of the incubation temperature, which indicates high absorption rate of 
mannitol molecules into the PDMS surface shortly after loading the channel (Figure 3.3C). 
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microfluidic PDMS channels incubated at (A) 25 °C and (B) 37 °C for 0.5 (●), 1.0 (■), 2.5 
(▲), and 4.5 () hours. (C) Absorption rate of [3H]-Diazepam into PDMS microfluidic 
channels at 25 °C (●) and 37 °C (○) for 0.5, 1, 2.5, and 4.5 hours. Results are the average ± 
the standard error of the mean collected from 5 different channels. Statistical difference in 
diazepam absorption rate as a function of solution temperature at a given incubation time 
point is identified by * when p < 0.05, ** when p < 0.01, and *** when p < 0.001. 
 
3.3.4 Correlation between Log P and Absorption in PDMS Microfluidic Channels 
 The partition coefficient, log P, of a given molecule depends on the 
hydrophilic/hydrophobic balance, which is dictated by its chemical structure. This report 
describes the absorption of a series of markers with different degrees of hydrophobicity 
reflected by their log P values, which span the log P range of the majority of therapeutic 
and diagnostic agents.[46, 47] Correlating the log P of different markers with their 
absorption profile will allow the prediction of absorption of therapeutic molecules in 
PDMS microfluidic devices as a function of incubation time and solution temperature. 
Results show that mannitol exhibited the lowest absorption (95% retrieval) in PDMS 
channels upon incubation for 0.5 hours at 37 ºC, which is not surprising given its 
hydrophilic nature (log P = -3.1) (Figure 3.8A). Dexamethasone (log P = 1.83) and 
phenytoin (log P = 2.47) also exhibited low absorption (> 90% retrieval) into PDMS 
channels upon incubation for 0.5 hours at 37 ºC. In comparison, increasing the log P of 
investigated molecules to 2.62 (rhodamine 6G) and 2.8 (diazepam) led to a substantial 
increase in molecular absorption in PDMS channels under the same experimental 
conditions. These results suggest that there is a log P “threshold” between 2.47 and 2.62 
where molecules with log P < 2.47 exhibit minimal absorption into PDMS surfaces 
whereas those with log P > 2.62 get extensively absorbed into PDMS channels. 
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 To better elucidate the difference in markers hydrophobicity, we used log P values 
to calculate the concentration of different marker molecules in octanol (equation 1) and 
normalized the concentration of each marker in this organic layer to that of mannitol. 
Results show that the calculated concentration of dexamethasone, phenytoin, rhodamine 6G, 
and diazepam is ~85,000-, 372,000, 525,000-, 794,000-folds the concentration of mannitol 
partitioning into the organic octanol layer, respectively, which clearly shows the significant 
difference in hydrophobicity of different molecules. Further, it shows the significant 
difference in hydrophobicity between phenytoin and rhodamine 6G despite the small 
difference in their log P values, which suggests that there is a log P “threshold” for 
extensive absorption into PDMS microfluidic devices. The relationship between log P of 
different markers and their observed absorption into PDMS microfluidic devices was 
consistent at all incubation time points up to 4.5 hours (Figure 3.8). 
 Our results are supported by earlier studies by Lee et al who examined the 
compatibility of different aqueous and organic solvents with PDMS-based microfluidic 
devices by measuring the partition of multiple organic solutes between bulk PDMS and 
different organic solvents.[68] Results of this investigation showed that aqueous solutions 
of rhodamine B (log P = 2.74)[67] and fluorescein (log P = -0.67)[69] exhibited different 
absorption profiles into bulk PDMS.[68] Specifically, fluorescein was not absorbed into 
PDMS whereas 60% of rhodamine B molecules got absorbed into bulk PDMS under the 
same experimental conditions.[68] These earlier results are in agreement with our findings 
and support the notion that absorption into PDMS depends on the solute’s log P value. It is 
important to note that an analysis of over 3000 drug candidates between 1960-2000 showed 
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PDMS walls.58, 59 Earlier studies showed that the contact angle for uncoated Sylgard 184 
PDMS 110º, which indicates the high hydrophobicity of the PDMS surface.[61] However, 
TiO2- and glass-coated PDMS channels have a significantly lower contact angle of 61º and 
35º, respectively.[61, 70] Consequently, we evaluated the effect of TiO2 and glass coatings 
on diazepam (log P = 2.8) absorption into microfluidic PDMS channels upon incubation for 
0.5 hour at 37 ºC (Figure 3.9). Results show that the percentage of retrieved diazepam 
increased from 4% for uncoated PDMS channels to 8% and 18% in TiO2- and glass-coated 
channels, respectively (Figure 3.9A). Therefore, diazepam absorption rate decreased 
significantly from 1.79 %/min/cm2 for uncoated PDMS channels to 1.73 %/min/cm2 and 
1.57 %/min/cm2 in TiO2- and glass-coated channels, respectively (Figure 3.9B). However, 
the decrease in diazepam absorption in TiO2- and glass-coated channels did not match the 
low absorption rate of marker molecules with log P < 2.47. These results suggest the 
potential of TiO2 and glass coatings in reducing the absorption of hydrophobic molecules 
(log P > 2.62) but coating conditions (e.g. number and thickness of coating layers) need to 
be further optimized to inhibit molecular absorption into microfluidic PDMS channels.   
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considering the log P of different solute molecules before using them in quantitative assays 
in microfluidic PDMS devices. 
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Chapter 4 
 
Development of an In Vitro Model of the Blood-Brain Barrier in Layered Microfluidic 
Channels 
 
 
4.1 Introduction 
The endothelial cells lining the capillaries that supply the brain with oxygen and 
nutrients present a highly regulated barrier known as the blood-brain barrier (BBB) [1, 2]. 
These endothelial cells are characterized by thick cell membranes, few endocytic vesicles, 
absence of fenestrae, and highly organized tight junctions, which restrict molecules’ 
diffusion from the blood circulation into the brain [1, 2]. These endothelial cells along with 
other supporting cells that contribute to the BBB integrity such as astrocytes [3], neurons 
[1], pericytes [2], and microglial cells [4] are collectively known as the neurovascular unit, 
which control the permeability of the BBB [3]. The integrity and function of the BBB is 
also regulated by several environmental conditions including flow-induced shear stress [1], 
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endothelial cell-to-cell contact [5], communication within the neurovascular unit [4], and 
the local concentration of secreted chemical factors [3]. The restrictive nature of the BBB 
allows only 2% of small molecular weight (< 500 Daltons) drugs to permeate from the 
systemic circulation and achieve therapeutic concentrations in the brain [6]. However, large 
molecular weight drugs (e.g. peptides, proteins, and nano-medicines) generally fail to 
diffuse across the BBB [1, 2]. Therefore, treatment of several neurological disorders such 
as Alzheimer disease, Huntington disease, stroke, and brain cancer is limited by the lack of 
new drug molecules that can effectively permeate across the BBB and achieve the desired 
therapeutic concentration in diseased brain cells [6]. 
Several groups focused their research efforts on understanding the cellular and 
molecular mechanisms that control and regulate the integrity and function of the BBB [7]. 
Other investigations relied on computational and experimental studies to predict the 
chemical structure and properties of an ideal drug candidate that can diffuse across the BBB 
[2, 6]. These mechanistic investigations catalyzed the development of in vitro models to 
represent the BBB [6, 7]. Many in vitro BBB models are established by culturing the 
endothelial cells on porous polycarbonate or polyester membranes with variable pore size 
using the conventional transwells system [7]. However, these endothelial monolayers 
typically exhibit low trans-endothelial electrical resistance (TEER) and high permeability 
values indicating the formation of a “leaky” barrier that is not representative of the BBB in 
vivo [7], which prompted the development of more sophisticated models that can mimic a 
complete neurovascular unit. 
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Microfluidic channels have been used to create many in vitro assays due to their 
ability to closely mimic the in vivo microenvironment [8] and utilize a small volume of the 
studied analytes compared to conventional analytical tools [9]. Poly(dimethylsiloxane) or 
PDMS is a commonly used material for fabrication of microfluidic channels used for cell 
culture due to its optical clarity [10], biocompatibility [11], and high oxygen diffusivity 
[12]. For example, embedding Ag/AgCl electrodes in the upper and lower microfluidic 
PDMS channels allowed real time quantitative assessment of the integrity of epithelial and 
endothelial cells cultured in layered microfluidic channels by monitoring the change in 
monolayer resistance [13]. 
In this article, we report the successful culture of mouse brain endothelial cells 
(b.End3) in layered microfluidic PDMS devices to develop a new in vitro BBB model that 
better mimics the restrictive transport behavior observed in vivo. We rely on the geometry 
and dimensions of the PDMS channels to drive the formation of a “restrictive” b.End3 
monolayer compared to conventional transwells. We examined the viability, morphology, 
and organization of b.End3 cells in layered microfludic channels as a functions of days in 
culture. We measured TEER across b.End3 monolayers established in layered microfluidic 
channels and conventional transwells as a function of days in culture as an indication of 
barrier integrity. We also compared the diffusion of mannitol and dextran (paracellular 
permeability markers) across b.End3 cell monolayers established in layered microfluidic 
channels to that observed in conventional transwells to investigate the difference in barrier 
properties among these BBB models and calculated their respective membrane porosity. In 
addition, we evaluated the functional expression of the P-glycoprotein (P-gp) efflux pump 
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by b.End3 cells in both in vitro models by measuring the apical-to-basolateral (AB) and 
basolateral-to-apical (BA) permeability of dexamethasone (a P-gp substrate) as a function 
of culture time. 
 
4.2 Materials and Methods 
4.2.1 Materials 
Poly(dimethylsiloxane) (Sylgard 184) was purchased from Dow Corning (Midland, 
MI). SU-850 was purchased from MicroChem (Newton, MA). Toluene and sterile 
fibronectin solution were purchased from Sigma-Aldrich (St. Louis, MO). [14C]-D-
mannitol (100 μCi/ml) was purchased from Moravek Biochemicals and Radiochemicals 
(Brea, CA). [3H]-Dexamethasone (1 mCi/ml) was purchased from American Radiolabeled 
Chemicals, Inc. (St. Louis, MO). Mouse brain endothelial cells (b.End3) were purchased 
from ATCC (Manassas, VA). Dulbecco’s modified eagle medium, fetal bovine serum, 0.05% 
trypsin, and live/dead cytotoxicity kits were purchased from Invitrogen Life Technologies 
Corporation (Carlsbad, CA). FITC-labeled 40K-dextran was generously gifted by Dr. 
Anuska Andjelkovic-Zochowska from the Department of Pathology and Neurosurgery at 
the University of Michigan. 
 
4.2.2 Design and Fabrication of Microfluidic Devices 
The microfluidic devices used for culture of b.End3 cells are composed of layered 
microfluidic channels (W = 2, 4, or 8mm; L = 4cm; H = 200µm) sandwiching a porous 
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membrane (0.4µm pore size), which were fabricated using soft lithography following 
established protocols [13, 14]. Briefly, PDMS prepolymer was mixed with the curing agent 
at a 10 (prepolymer)/1 (curing agent) weight ratio before casting onto two 4 inch silicon 
wafers containing a 200μm thick positive relief pattern. The mixture was cured at 60°C for 
2 hours before peeling the PDMS layer off the silicon wafer. Access holes were punched 
with a 16 gauge blunt syringe (1.65 mm outer diameter) forming the inlet and outlet holes 
for each channel. We spun coated a PDMS/toluene mixture prepared at a 3/2 weight ratio 
on a clean glass slide for 1 minute to generate a thin mortar layer, which was used to glue 
the top and bottom PDMS layers. Ag/AgCl recording electrodes were embedded in 500μm 
x 500μm side channels when fabricating microfluidic devices for measurement of 
transendothelial electrical resistance (TEER) across b.End3 monolayers following a 
published procedure [13]. Polyester membranes with an average pore size of 0.4µm were 
sandwiched between the aligned top and bottom PDMS layers and glued together before 
curing for 1 hour until the PDMS mortar completely hardened. Pipette tips (100μl) were 
inserted into the inlets and outlets of the top and bottom channels to serve as medium 
reservoirs before exposure to plasma oxygen for 5 minutes. Sterile fibronectin solution 
(25μg/ml) was loaded into the top PDMS channel for 24 hours to coat the polyester 
membrane followed by exposure of the microfluidic device to UV radiation for sterilization 
before seeding of b.End3 cells. 
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4.2.3 Cell Culture 
Frozen mouse brain endothelial cells (b.End3) were thawed at 37°C before mixing 
with 3mL of culture medium, centrifuging at 1000rpm for 3 minutes, aspirating the 
supernatant, suspending the cell pellet in 10mL of culture medium, transferring cell 
suspension to a T75 flask, and incubating the cells in a humidified 5% CO2 incubator at 
37°C while changing the culture medium every 48 hours. Cultured b.End3 cells were 
passaged after reaching 80% confluence by incubating with 5mL of 0.05% Trypsin-EDTA 
solution for 3 minutes at 37°C to collect the cell pellet for splitting into new T75 flasks or 
seeding onto fibronectin-coated membranes in microfluidic devices or conventional 
transwells at a seeding density of 270 cells/mm2. 
 
4.2.4 Assessment of Viability of b.End3 Cells 
Endothelial b.End3 cells cultured in layered microfluidic channels were stained 
using the live/dead cytotoxicity kit (Life Technologies Corporation, Carlsbad, CA) 
following manufacturer’s protocol. Briefly, 1µL calcein AM and 1µL ethidium 
homodimer-1 were added to 1mL of the culture medium before adding 16µL of this 
mixture to b.End3 cells cultured in the top channel and incubating for 20 minutes at 37ºC 
under normal culture conditions. Live b.End3 cells were stained green while dead cells 
were stained red and both were visualized using an inverted fluorescent microscope (Nikon, 
New York, NY) at 500nm and 600nm, respectively. The number of live and dead b.End3 
cells observed at the inlet, center, and outlet of the top microfluidic channel was counted in 
the fluorescent images (1.7mm x 0.88 m) captured at a 10X magnification. 
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The angle (θ) between cultured b.End3 cells and the longitudinal (X) axis of the top 
channel in captured fluorescent images (10X magnification) was measured using Photoshop 
CS4 (Adobe, San Jose, CA) to determine the change in cell alignment at the channel’s inlet, 
center, and outlet as a function of culture time. The variance of the angle measurements is 
then calculated using equation (1) where σ2 is the variance, N is the number of data points, 
xi is each specific data point, and µ is the mean: 
ߪଶ ൌ 	 ଵே	∑ ሺݔ௜ െ 	ߤሻଶே௜ୀଵ  ---------------------------------------------------------------- Equation 1 
 
4.2.5 Trans-Endothelial Electrical Resistance (TEER) across b.End3 Cell 
Monolayers 
Trans-endothelial electrical resistance (TEER) of confluent b.End3 cell monolayers 
cultured onto conventional transwells was measured using standard chopstick electrodes 
(World Precision Instruments, Sarasota, FL) while accounting for the intrinsic resistance of 
blank filters. Resistance across b.End3 monolayers cultured in layered microfluidic 
channels was measured on daily basis following our published protocol [13]. Briefly, 
impedance spectra were taken using an Autolab potentiostat/galvanostat at 0.1V of 
alternating current passing between the two embedded electrodes within layered 
microfluidic channels. Frequency range between 10Hz to 1.00MHz was used to yield a 
total of 64 impedance measurements. The control impedance spectra measured before 
seeding the cells were subtracted from the measured impedance spectra with b.End3 cells to 
eliminate their contribution to the calculated resistance. We developed a MATLAB code 
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(The MathWorks Inc., Natick, MA) using its optimization toolbox to resolve the TEER 
values, which were normalized to the surface area of the cell monolayers to calculate the 
resistance in Ω.cm2. 
 
4.2.6 Paracellular Permeability across b.End3 Cell Monolayers 
We investigated the transport of two paracellular permeability markers namely 
[14C]-mannitol (182 Da, 11.32µM) and FITC-labeled 40K-dextran (40 kDa, 0.117µM) 
across b.End3 cell monolayers cultured in conventional transwells and layered microfluidic 
channels after 3, 6, 9, 12, 15, 18, and 21 days in culture. In both transwells and layered 
microfluidic channels, b.End3 cells were seeded at a seeding density of 270 cells/mm2 onto 
porous polyester membranes pretreated with fibronectin and allowed to grow under normal 
culture conditions. The culture medium was removed from the apical (top) and basolateral 
(bottom) compartments before washing the b.End3 monolayers twice with warm (37°C) 
PBS solution prior to starting the transport study. The PBS solution in the apical 
compartment was replaced with different marker solutions before incubating different 
devices at 37°C, 95% relative humidity, and 5% CO2 for 60 minutes. The PBS solution in 
the receiver compartment in layered microfluidic channels and transwells was collected and 
replaced with fresh PBS every 10 minutes for 60 minutes. At the end of the 1 hour 
incubation time, PBS solutions in both the donor and receiver compartments were also 
collected. Collected PBS solutions containing radiolabeled markers were mixed with 1mL 
of the liquid scintillation fluid (GMI Inc., Ramsey, MN) and analyzed using the Beckman 
LS6500 Liquid Scintillation Counter (Beckman Coulter Inc., Brea, CA) to determine the 
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concentration of each marker using a standard calibration curve. Similarly, the fluorescence 
of FITC-labeled 40K-dextran was measured (λex = 488nm and λem = 520nm) using a 
fluorescence plate reader (Thermo Fisher Scientific Inc., Wayne, MI) to calculate dextran 
concentration in collected solutions using a calibration curve. 
The permeability of a given molecule across the b.End3 monolayer was calculated 
using the following differential equation derived from Fick’s Law [15]: 
ܲ ൌ 	௏್ೌೞ೚೗ೌ೟೐ೝೌ೗	ൈ	
∆಴್ೌೞ೚೗ೌ೟೐ೝೌ೗
∆೟
஺	ൈ	஼ೌ೛೔೎ೌ೗  ---------------------------------------------------------- Equation 2 
Where P denotes solute permeability (cm/sec), V is the PBS volume in the basolateral 
compartment, A is the surface area of the b.End3 monolayer, C is solute concentration in 
the apical compartment, and ∆C is the change in solute concentration in the basolateral 
compartment as a function of time. It is important to note that the transfer of solutes from 
the apical to the basolateral compartment does not depend on solute concentration and 
varies only with the incubation time. 
 
4.2.7 Assessment of P-glycoprotein Activity in b.End3 Cell Monolayers 
Functional expression of P-glycoprotein (P-gp) efflux pump by b.End3 cells 
cultured in transwells and layered microfluidic channels was investigated by measuring the 
apical-to-basolateral (AB) and basolateral-to-apical (BA) permeability of [3H]-
Dexamethasone (0.004µM), which is a substrate for the P-gp efflux pump. Before starting 
the transport experiment, the culture medium in the apical and basolateral compartments in 
the transwells and channels were replaced with fresh PBS preheated at 37°C after washing 
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the cell monolayer twice. PBS solutions were then aspirated and replaced with [3H]-
Dexamethasone in the apical (top) compartment for half of the total number of channels 
and transwells. The basolateral (bottom) compartment in the other half of the channels and 
transwells was filled with the radioactive marker. All other experimental conditions and 
solution retrieval procedures were similar to those used in the paracellular permeability 
studies. We calculated the apical-to-basolateral (AB) and basolateral-to-apical (BA) 
permeability of [3H]-Dexamethasone using equation 5. 
 
4.3 RESULTS 
4.3.1 Effect of Dimensions of Microfluidic Channels on b.End3 Viability and 
Morphology 
The design of our microfluidic device incorporates two layered microfluidic 
channels that sandwich a polyester membrane (0.4µm pore size) along the entire length of 
the channel, which was used to culture b.End3 cells (Figure 4.1A). The device is designed 
to incorporate a cross section between the top and bottom channels sufficient to allow 
measurement of solute’s permeability across b.End3 cell monolayers while maintaining an 
elongated geometric shape and scaled down dimensions. The elongated rectangular shaped 
channel serve to guide endothelial cell growth, which has been shown to enhance 
endothelial cell growth and differentiation [16]. The geometry of our device also serves to 
mimic the blood vessel much more closely compared to the circular design of the transwells. 
The small dimensions (W = 2mm; L = 4cm; H = 200µm) of the 2mm-wide microfluidic 
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results show that the number of viable b.End3 cells significantly increased from 435±21 
cells/mm2 after 3 days in culture to 565±35 cells/mm2 after 6 days (α = 0.05) and remained 
constant up to 21 days (Figure 4.2A). Similarly, the number of b.End3 cells cultured in 
transwells increased from 400±25 cells/mm2 after 3 days in culture to 538±28 cells/mm2 
after 6 days (Figure 4.2A). However, the number of b.End3 cells gradually declined from 
550±54 cells/mm2 after 12 days in culture down to 473±25 cells/mm2 after 21 days (Figure 
4.2A). The decline in number of viable b.End3 cells is supported by earlier reports showing 
shorter viability span of b.End3 cells cultured in transwells compared to microfluidic 
devices [17]. 
We measured the angle (θ) between the spindle of b.End3 cells and the longitudinal 
axis of the microfluidic channels as a function of days in culture. Fluorescent images of 
b.End3 cells show a 50° angle (θ) between b.End3 cells and the longitudinal axis of the 
microfluidic channels after 3 days in culture, which indicates a random organization of the 
cultured cells at early time points (Figure 4.2B). However, this angle (θ) gradually declined 
with the increase in culture time reaching 28° after 21 days, which indicates gradual 
alignment of bEnd.3 cells along the length of the microfluidic channel that increased with 
culture time (Figure 4.2B). In comparison, the angle (θ) between the spindle of b.End3 
cells and the cross-sectional diameter of the transwells was 51° after 3 days in culture and 
dropped to only 44° after 21 days in culture indicating random organization of b.End3 cells 
throughout the culture time (Figure 4.2B). The variance (σ2) in angle measurement showed 
a steady decline in spindle angle for b.End3 cells cultured in microfluidic channels 
compared to those cultured in transwells, which further confirms the alignment of b.End3 
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(31.8 x 10-6 cm/s) after 3 days in culture (Figure 4.4A). However, permeability of [14C]-
mannitol across b.End3 cell monolayers cultured in microfluidic channels gradually 
decreased with the increase in culture time compared to the observed [14C]-mannitol 
permeability across b.End3 cell monolayers cultured in conventional transwells (Figure 
4.4A). For example, permeability of [14C]-mannitol across b.End3 cell monolayers 
cultured in 2mm-wide microfluidic channels dropped to 13.8 x 10-6 cm/s compared to 36.7 
x 10-6 cm/s observed in transwells after 6 days in culture (2.7-fold decrease in permeability) 
(Figure 4.4A). After 9 days in culture, permeability of [14C]-mannitol across b.End3 cell 
monolayers cultured in 2mm-wide microfluidic channels dropped further to 3.4 x 10-6 cm/s 
compared to 27.7 x 10-6 cm/s observed in the transwells (8.2-fold decrease in permeability) 
(Figure 4.4A). Permeability of [14C]-mannitol across b.End3 cell monolayers cultured in 
2mm-wide microfluidic channels was 3.2 x 10-6, 3.3 x 10-6, 3.3 x 10-6, and 3.5 x 10-6 cm/s 
after 12, 15, 18, and 21 days in culture, respectively, which is 5.7- to 15.1-fold lower than 
the observed permeability across b.End3 cell monolayers cultured in 12-well transwells at 
the same time points (Figure 4.4A). 
Results show similar permeability of 40K-dextran across b.End3 cell monolayers 
cultured in transwells (2.3 x 10-6 cm/s) and 2mm-wide microfluidic channels (2.0 x 10-6 
cm/s) after 3 days in culture (Figure 4.4B). However, permeability of 40K-dextran across 
b.End3 cell monolayers cultured in microfluidic channels gradually decreased with the 
increase in culture time compared to the observed 40K-dextran permeability across b.End3 
cell monolayers cultured in conventional transwells (Figure 4.4B). For example, 
permeability of 40K-dextran across b.End3 cell monolayers cultured in 2mm-wide 
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microfluidic channels dropped to 0.6 x 10-6 cm/s compared to 1.7 x 10-6 cm/s observed in 
transwells after 6 days in culture (2.8-fold decrease in permeability) (Figure 4.4B). After 9 
days in culture, permeability of 40K-dextran across b.End3 cell monolayers cultured in 
2mm-wide microfluidic channels dropped further to 0.1 x 10-6 cm/s compared to 1.1 x 10-6 
cm/s observed in the transwells (11-fold decrease in permeability) (Figure 4.4B). 
Permeability of 40K-dextran across b.End3 cell monolayers cultured in 2mm-wide 
microfluidic channels remained constant at 0.1 x 10-6 cm/s between 12 and 21 days in 
culture, which is 15- to 21-fold lower than the observed permeability across b.End3 cell 
monolayers cultured in 12-well transwells at the same time points (Figure 4.4B). 
The permeability profiles of [14C]-mannitol and 40K-dextran across b.End3 cell 
monolayers established in 2mm-wide microfluidic device indicate the development of a 
stable and “restrictive” barrier after 9 days in culture, which retains its integrity for up to 21 
days (Figure 4.4, Panels A & B). In comparison, b.End3 cell monolayers established in 
12-well transwells achieve their maximum integrity (i.e. lowest permeability) on day 9 but 
rapidly lose their integrity as indicated by the increase in permeability of [14C]-mannitol 
and 40K-dextran on the following days in culture (Figure 4.4, Panels A & B). It is also 
important to note that b.End3 monolayers established in 2mm-wide microfluidic channels 
can discriminate between small molecules like mannitol and macromolecules like dextran 
shown by the > 30-fold higher mannitol permeability. This size selectivity towards 
diffusing molecules indicates the formation of tight junction complexes between adjacent 
endothelial cells in our microfluidic channels, which is one of the key properties of the 
BBB in vivo [1, 2]. 
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calculated the radius (R) of the pores of the tight junctions using the following Renkin 
function equation. 
ܨ ቀ௥ோቁ ൌ ሺ1 െ
௥
ோሻଶሾ1 െ 2.104 ቀ
௥
ோቁ ൅ 2.09 ቀ
௥
ோቁ
ଷ െ 0.95 ቀ௥ோቁ
ହሿ   -------------------- Equation 3 
Where the Renkin function [ܨ ቀ௥ோቁ] mathematically describes the relationship between the 
radius of the diffusing molecule (r) and the pore radius of the tight junctions (R) [26]. 
The following flux equation provides a relationship between the permeability (P) of 
a diffusing marker molecule and the Renkin function [ܨ ቀ௥ோቁ]. 
ܲ ൌ ఢ஽ிሺ
ೝ
ೃሻ
ఋ 	 ---------------------------------------------------------------------------- Equation 4 
where ߳  is the porosity of the b.End3 monolayer, D is the diffusion coefficient of the 
evaluated marker molecule, and ߜ is the distance traversed by the marker molecule down a 
concentration gradient [26]. We used the diffusion coefficients (D) of mannitol (9.65 x10-6 
cm/s) and 40K-dextran (5.1 x 10-7 cm/s) with our permeability results (Figure 4.4, Panels 
A&B) to solve equation 4 for the Renkin function ܨሺ௥ோሻ and 
ఢ
ఋ at different time points. We 
used Matlab R2009a to solve the ܨሺ௥ோሻ polynomial (Equation 3) and obtain R assuming that 
the radii (r) of mannitol and 40K-dextran are 0.34nm [27] and 3nm [28], respectively. 
Results show that the average radius of the tight junctions pores (R) for b.End3 cell 
monolayers cultured in transwells drops from 48.8 to 45.1 and 40.5 nm after 3, 6, and 9 
days in culture, respectively (Figure 4.4C). At longer time points, the radius of the tight 
junctions pores (R) for b.End3 cell monolayers cultured in transwells gradually increases 
reaching 53.9 nm after 21 days in culture (Figure 4.4C). In comparison, the radius of the 
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tight junctions pores (R) for b.End3 cell monolayers cultured in layered microfluidic 
channels started at 46.1 nm after 3 days in culture and gradually decreased to 33.8 nm (day 
6), 28.4 nm (day 9), and remained relatively constant for 21 days in culture (Figure 4.4C). 
Lower porosity (R) of b.End3 monolayers established in layered microfluidic channels 
compared to conventional transwells is statistically significant (α = 0.005) and confirms the 
formation of a restrictive barrier in the microfluidic device. 
 
4.3.5 Effect of Channel Width on Barrier Properties of b.End3 monolayers 
Earlier reports relied on flow-mediated shear stress to align endothelial cells with 
the direction of the flow, which increased the expression and localization of tight junctions 
proteins between adjacent cells resulting in the formation of more restrictive models of the 
BBB in vitro [17, 18, 29, 30]. Other reports showed the ability to direct endothelial cells to 
follow the shape of microfluidic devices used for their culture [19-23]. Therefore, we 
hypothesized that controlling the narrow width of the microfluidic channels (2mm) used for 
culture of b.End3 cells will direct the cells to align along the longitudinal axis of the 
channel, which will enhance cell-cell contact, formation of the tight junctions, and result in 
the formation of a restrictive barrier without incorporating complex accessories to allow 
laminar flow through our channels. Alignment of b.End3 cells (Figure 4.2B), high TEER 
values (Figure 4.3B), and low permeability of [14C]-mannitol and 40K-dextran across 
b.End3 cell monolayers established in 2mm-wide microfluidic channels clearly indicate the 
formation of a viable and restrictive barrier in our microfluidic devices. To further validate 
the role of channel width in guiding b.End3 cell alignment and formation of a restrictive 
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BBB, we fabricated layered microfluidic channels that are 4mm and 8mm wide while 
keeping the same channel’s length (4cm) and height (200µm) and used them for culture of 
b.End3 cells under the same experimental conditions. 
Results show that increasing channel width to 4mm did not cause a significant 
change in TEER across b.End3 cell monolayers compared to those cultured in 2mm-wide 
channels (Figure 4.3B). However, increasing channel width to 8mm (4 folds) caused a 
significant drop in TEER values compared to b.End3 monolayers established in 2mm-wide 
channels (Figure 4.3B). Specifically, TEER started at 28 Ohms.cm2 directly after seeding 
and gradually increased to reach 62, 74, 87 Ohms.cm2 on days 1, 2, and 3, respectively, 
before stabilizing around 90 Ohms.cm2 till day 21 (Figure 4.3B). This dramatic drop in 
TEER values despite of identical seeding density and culture conditions clearly show the 
contribution of channel width to the organization of b.End3 cells in the channels and their 
ability to form a tight monolayer. 
We investigated the permeability of [14C]-mannitol across b.End3 monolayers 
established in 4mm- and 8mm-wide microfluidic channels and compared the results to 
those observed in 2mm-wide channels (Figure 4.5). Specifically, permeability of [14C]-
mannitol was 5.01 x 10-6, 5.28 x 10-6, 5.12 x 10-6, 3.75 x 10-6, and 5.13 x 10-6 on day 9, 12, 
15, 18, and 21, respectively, which are statistically higher than mannitol permeability 
across b.End3 cell monolayers established in 2mm-wide channels (Figure 4.5). 
Permeability of [14C]-mannitol across b.End3 cell monolayers established in 8mm-wide 
channels were ~3-fold higher than that observed in 2mm-wide channels reaching 12.1 x 10-
6, 12.5 x 10-6, 11.5 x 10-6, 10.8 x 10-6, and 12.2 x 10-6 cm/s on days 9, 12, 15, 18, and 21, 
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layered microfluidic channels, which will allow better cell-to-cell contact, increase the 
surface-to-volume ratio, minimize the dilution of secreted factors, and reduce the needed 
volume to evaluate the transport of different markers [14, 16, 33-35]. We achieved this goal 
by adjusting the dimensions of the top channel to resemble a blood capillary while 
maintaining a large aspect ratio and a small total volume (17 µl). Starting with 2mm-wide 
channels, it appears that channel width and geometry enhance b.End3 cell-to-cell contact 
and guide their alignment along the longitudinal axis of the channel, which is supported by 
previous reports utilizing microfluidic devices with similar width and height [17]. 
Alignment of b.End3 cells and enhanced cell-to-cell contact in 2mm-wide layered 
microfluidic channels enhanced barrier properties as shown by the 2.5-folds increase in 
TEER compared to b.End3 cells cultured in conventional transwells. Further, b.End3 
monolayers cultured in 2mm-wide layered microfluidic channels retained their viability and 
integrity for 21 days. In comparison, b.End3 cells cultured in the transwells maintained 
their integrity for only 6-10 days after their seeding indicated by the increase in 40K-
dextran and [14C]-mannitol permeability at longer days in culture. The observed short span 
of barrier integrity in the transwells is supported by earlier reports [36] [35]. Renkin 
function, a frequently used mathematical model that can resolve the radius of the tight 
junctional pores in both endothelial and epithelial monolayers, clearly demonstrated that 
b.End3 cells cultured in 2mm-wide microfluidic channels indeed form “tighter” and more 
“restrictive” tight junctions shown by the ~1.5-fold reduction in the radius of the 
intercellular space. While the in vivo tight junctional pores have been shown to be 0.8 nm 
[37], developing an in vitro model of the BBB where barrier integrity is enhanced by 
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controlling the dimensions of the microfluidic channel without the need for flow-mediated 
shear stress is a significant step towards the development of simplified yet robust in vitro 
models. 
Previous works have indicated that geometry of the cell culture micro-environment 
not only can help define vascular architectures [21] and cell adhesion [38], it can also 
influence cell growth, differentiation, and apoptosis [16]. It was further supported by the 
fact that geometry of cell-to-cell contact, which our channel design has affected through 
angle alignment of b.End3 cell culture, can also affect tight junction formations [39]. 
Therefore we hypothesized early on that the cell alignment observed through fluorescent 
images was a result of small width of the channels and plays an important role in assisting 
the formation of tight junctions. This effect was demonstrated by increasing the width of 
the microfluidic channels from 2 mm to 4 and 8 mm. The dramatic drop in TEER values 
and the corresponding increase in permeability of [14C]-mannitol across b.End3 cell 
monolayers established in 8mm-wide channels compared to the monolayers established in 
2mm-channels clearly indicate the formation of “loose” junctions and a more “leaky” 
barrier. Furthermore, the observed low AB permeability and high BA permeability of 
dexamethasone across b.End3 monolayers cultured in 2mm-wide microfluidic channels 
confirm the expression of functional P-gp by cultured cells starting on day 12 and retained 
till 21 days in culture. 
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4.5 CONCLUSIONS 
We report the successful culture of brain endothelial cells (b.End3) in layered 
microfluidic channels forming a viable monolayer that exhibits restrictive transport 
properties indicated by higher TEER values and lower mannitol and dextran permeability 
compared to b.End3 monolayers cultured in conventional transwells. Further, b.End3 cells 
cultured in microfluidic devices express functional P-gp at higher levels compared to 
transwells. Therefore, b.End3 cell monolayers cultured in the described microfluidic 
devices is a representative in vitro model of the blood-brain barrier. 
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Chapter 5 
 
 
Development of a 3D In Vitro Model of the Blood-Brain Barrier in Layered 
Microfluidic Channels 
 
 
5.1 INTRODUCTION 
The endothelial cells lining the capillaries that supply the brain with oxygen and 
nutrients present a highly regulated transport barrier known as the blood-brain barrier 
(BBB). These endothelial cells are characterized by thick cell membranes, low number of 
endocytic vesicles, absence of fenestrae, and highly organized tight junctions that restrict 
molecular diffusion across the paracellular space [1-3]. The integrity and function of the 
BBB is regulated by several factors including endothelial cell-to-cell contact [4], 
communication with other supporting cell types such as astrocytes and pericytes [2], and 
the local concentration of secreted chemical factors [5, 6]. Due to the presence of this 
highly functional barrier, only 2% of small-molecule drugs (< 500 Daltons) can cross the 
BBB to achieve their effective concentrations and nearly none of the existing large-
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molecule drugs can cross the BBB [7]. Only a few central nervous system (CNS) disorders, 
such as depression, epilepsy, chronic pain, and affective disorders, respond to clinical 
treatments by the 2% of small-molecule drugs that we have; on the other hand, many more 
serious CNS disorders cannot be effectively treated by these small therapeutic molecules 
[7].  
The inability of conventional drug molecules to cross the BBB has, in some cases, 
forced drug development programs to go forward without the consideration of BBB 
transport at all. This led to the development of craniotomy-based drug delivery method 
where a hole is drilled in the head, and drugs are directly administered to the brain, thus 
bypassing the BBB altogether [7]. However, drug molecules administered this way tend to 
stay at the injection site and cannot effectively penetrate the brain parenchyma. With such 
limited penetration capability, only 1% of the brain volume is reached, making this method 
ineffective against most, if not all, brain diseases [7]. Clinical research has also shown that 
osmotic modification of the BBB can increase the delivery of drug molecules, specifically 
chemotherapeutic agents for the treatment of brain tumors. This method, coupled with 
intravenous infusion of chemotherapeutic agents [8], has been found to prolong survival of 
patients with high-grade gliomas by 10-12 months [9]; however, this therapeutic method is 
associated with cognitive deterioration or changes in the CNS detectable by Magnetic 
Resonance Imaging [10]. In comparison to the limitations of methods such as the 
craniotomy-based drug delivery system and osmotic modification of the BBB, if drug 
molecules administered intravenously or intracarotidly are capable of taking advantage of 
the transport systems, they have the potential to become much more effective at penetrating 
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the BBB while minimizing side effects at the same time. Drug molecules capable of such 
maneuvers have the ability to reach nearly all of the neurons in the brain since every neuron 
is supported by its own capillary vessel [7]; however, it requires innovative drug-targeting 
systems that have the capability of traversing through the BBB. Development of such 
system cannot begin until detailed molecular and cellular biology of the BBB are revealed; 
and obtaining such information requires an accurate and cost-effective in vitro BBB model 
that can be used repeatedly for drug screening and experimentation. 
Realizing the importance of in vitro BBB models, many groups have attempted to 
construct such model using both primary and immortalized cell lines. Primary endothelial 
cells isolated from bovine, human, porcine, and rodent are typically used in modeling the 
BBB [4]. Among all such established models, one porcine model demonstrated relatively 
high trans-endothelial electrical resistance (TEER) and low permeability [4], which are key 
characteristics of the BBB. Despite the ethical questions and the logistical difficulties of 
obtaining human brain tissue, there have been reports of established human BBB models; 
these models, however, are less robust than porcine models according to published data [4]. 
All primary models suffer from several disadvantages. Primary cells are expensive to 
obtain and the reconstitution process is time consuming. Furthermore, the homogeneity of 
obtained cells is difficult to determine, and can be easily contaminated with neighboring 
cell types such as the pericytes [4]. In recent years, immortalized brain endothelial cell lines 
have been more commonly used than primary cell lines due to their ease of manipulation 
and reproducibility. There are currently more than 20 endothelial cell lines available and 
virtually all of them have been used to establish in vitro BBB models with published results 
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[4]. Many of these models utilize transwell system, which is the standard tool for in vitro 
drug screening. The major issue that such models suffer is leaky monolayer formation 
which results in low TEER and high permeability values. Since these models did not 
generate BBB characteristics, it is very difficult to use them for BBB related studies. We 
believe that the reasons for the failed mimicry of the restrictive transport properties of the 
BBB can be due to the formation of “loose” tight junctions between adjacent endothelial 
cells, lower expressions of specific carriers, or limited cell viability. This can be attributed 
to the lack of proper micro-environments and efficient integration of endothelial and neural 
cells in a model that allow cell-to-cell communication necessary to induce the proper 
differentiation of brain capillary endothelial cells, formation of restrictive tight junctions, 
and functional expression of different transporters at the levels present in vivo. 
In this article, we report the successful culture of mouse brain endothelial cells 
(b.End3) with pericytes and astrocytes co-cultured in layered microfluidic PDMS devices to 
develop a new 3D in vitro BBB model that successfully mimics the restrictive transport 
properties observed in vivo. We rely on the dimensions of the channels and the surface to 
volume ratio to increase cell-to-cell contact and pericytes and astrocytes to influence the 
development and differentiation of the b.End3 monolayers. We compared the permeability 
of paracellular transport markers mannitol and urea across the monolayers to that observed 
in vivo to observe the difference in transport properties of the BBB model and calculated 
the Renkin function. Furthermore, we measured TEER across b.End3 monolayers 
established in our system to investigate the barrier integrity. We then modified the bottom 
layer of the channel design where astrocytes were grown in order to demonstrate the 
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distance effect of neutrophic factors on b.End3 monolayers cultured in layered microfluidic 
channels. Finally, we evaluated the functional expression of the P-glycoprotein (P-gp) 
efflux pump to determine the existence of these critical proteins in our BBB model. 
 
5.2 MATERIALS AND METHODS 
5.2.1 Materials 
Poly(dimethylsiloxane) (Sylgard 184) was purchased from Dow Corning (Midland, 
MI). SU-850 was purchased from MicroChem (Newton, MA). Toluene and sterile 
fibronectin solution were purchased from Sigma-Aldrich (St. Louis, MO). [14C]-D-
mannitol (100 μCi/ml) and [14C]-urea (100 μCi/ml) were purchased from Moravek 
Biochemicals and Radiochemicals (Brea, CA). [3H]-Dexamethasone (1 mCi/ml) was 
purchased from American Radiolabeled Chemicals, Inc. (St. Louis, MO). Mouse brain 
endothelial cells (b.End3) and Astrocyte type I clone (C8-D1A) were purchased from 
ATCC (Manassas, VA). Mouse pericytes were generously gifted by Dr. Anuska 
Andjelkovic from the University of Michigan. Dulbecco’s modified eagle medium, fetal 
bovine serum, 0.05% trypsin, non-essential amino acids, and live/dead cytotoxicity kits 
were purchased from Invitrogen Life Technologies Corporation (Carlsbad, CA). Interferon-
gamma was purchased from R&D Systems (Minneapolis, MN).   
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5.2.2 Design and Fabrication of Microfluidic Devices 
The microfluidic devices used for culture of b.End3 cells are composed of layered 
microfluidic channels (W = 2mm; L = 4cm; H = 0.2, 0.6, or 1mm) sandwiching a porous 
membrane, which were fabricated using soft lithography following established protocols 
[11, 12]. Briefly, PDMS prepolymer was mixed with the curing agent at a 10 (prepolymer) / 
1 (curing agent) weight ratio before casting onto two 4 inch silicon wafers containing a 200 
μm thick positive relief pattern. The mixture was cured at 60 °C for 2 hours before peeling 
the PDMS layer off the silicon wafer. Access holes were punched with a 16 gauge blunt 
syringe (1.65 mm outer diameter) forming the inlet and outlet holes for each channel. We 
spun coated a PDMS/toluene mixture prepared at a 3/2 weight ratio on a clean glass slide 
for 1 minute to generate a thin mortar layer, which was used to glue the top and bottom 
PDMS layers. Ag/AgCl recording electrodes were embedded in 500 μm x 500 μm side 
channels when fabricating microfluidic devices for measurement of TEER across b.End3 
monolayers following a published procedure.[12] Polyester membranes with an average 
pore size of 400 nm were sandwiched between the aligned top and bottom PDMS layers 
and glued together before curing for 1 hour until the PDMS mortar completely hardened. 
Pipette tips (100 μl) were inserted into the inlets and outlets of the top and bottom channels 
to serve as medium reservoirs before exposure to plasma oxygen for 5 minutes. Sterile 
fibronectin solution (25 μg/ml) was loaded into the top PDMS channel for 24 hours to coat 
the polyester membrane followed by exposure of the microfluidic device to UV radiation 
for sterilization before seeding of b.End3 cells and mouse pericyte cells. 
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5.2.3 Cell Culture 
Mouse brain endothelial cells (b.End3) were thawed at 37 °C before mixing with 3 
mL of culture medium, centrifuging at 1000 rpm for 3 minutes, aspirating the supernatant, 
suspending the cell pellet in 10 mL of culture medium, transferring cell suspension to a T75 
flask, and incubating the cells in a humidified 5% CO2 incubator at 37 °C while changing 
the culture medium every 48 hours. Cultured b.End3 cells were passaged after reaching 80% 
confluence by incubating with 5 mL of 0.05% Trypsin-EDTA solution for 3 minutes at 
37 °C to collect the cell pellet for splitting into new T75 flasks or seeding onto fibronectin-
coated membranes in microfluidic devices or conventional transwells at a seeding density 
of 270 cells/mm2. Astrocytes were cultured under the same conditions using Dulbecco’s 
Modified Eagle’s Medium (30-2002) with 10% FBS based on ATCC’s recommendation. 
Mouse pericytes were thawed at 37 °C and directly put into a T75 flask, and 
incubating the cells in a humidified 5% CO2 incubator at 31 °C while changing the culture 
medium every 24 hours. Cultured mouse pericytes were passaged after reaching 80% 
confluence by incubating with 3 mL of 0.05% Trypsin-EDTA solution for 5 minutes at 
31 °C to collect the cell pellet for splitting into new T75 flasks or seeding onto back-side of 
the fibronectin-coated membranes in microfluidic devices or conventional transwells at a 
seeding density of 100 cells/mm2. 
 
5.2.4 Assessment of Viability of b.End3 and Pericyte Cells 
Endothelial b.End3 cells, mouse pericytes, and mouse astrocytes were cultured in 
layered microfluidic channels were stained using the live/dead cytotoxicity kit (Life 
106 
Technologies Corporation, Carlsbad, CA) following manufacturer’s protocol. Briefly, 1 µL 
calcein AM and 1 µL ethidium homodimer-1 were added to 1 mL of the culture medium 
before adding 16 µL of this mixture to b.End3 cells cultured in the top channel and 
incubating for 20 minutes at 37 ºC under normal culture conditions. Live b.End3 cells and 
pericytes were stained green while dead cells were stained red and both were visualized 
using a fluorescent microscope (Nikon, New York, NY) at 500 nm and 600 nm, 
respectively. Number of live and dead b.End3 cells observed at the inlet, center, and outlet 
of the top microfluidic channel was counted in the fluorescent images captured at a 10X 
magnification. The angle between cultured b.End3 cells and the longitudinal (X) axis of the 
top channel in captured fluorescent images (10X magnification) was measured using 
Photoshop CS4 (Adobe, San Jose, CA) to determine the change in cell alignment as a 
function of culture time. Similarly, we measured the shape index of cultured b.End3 cells 
using ImageJ 1.44p software (NIH, Washington D.C.). The variance of the angle 
measurements is then calculated using equation (2) where sigma^2 is the variance, N is the 
number of data points, xi is each specific data point, and u is the mean: 
 
5.2.5 Trans-Endothelial Electrical Resistance across b.End3 Cell Monolayers 
Trans-endothelial electrical resistance (TEER) of confluent b.End3 cell monolayers 
cultured onto conventional transwells was measured using standard chopstick electrodes 
(World Precision Instruments, Sarasota, FL) while accounting for the intrinsic resistance of 
blank filters. Resistance across b.End3 monolayers cultured in layered microfluidic 
channels were measured on daily basis following our published protocol.[12] Briefly, 
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impedance spectra are taken using an Autolab potentiostat/galvanostat at 0.1 V of 
alternating current passing between the two embedded electrodes within layered 
microfluidic channels. Frequency range between 10 Hz to 1.00 MHz was used to yield a 
total of 64 impedance measurements. The control impedance spectra measured before 
seeding the cells were subtracted from the measured impedance spectra with b.End3 cells to 
eliminate their contribution to the calculated resistance. We developed a MATLAB code 
(The MathWorks Inc., Natick, MA) using its optimization toolbox to resolve the TEER 
values, which were normalized to the surface area of the cell monolayers to calculate the 
resistance in Ω.cm2. 
 
5.2.6 Paracellular Permeability across b.End3 Cell Monolayers 
We investigated the transport of a paracellular permeability marker [14C]-mannitol 
(182 Da) across b.End3 and pericyte co-culture layer in layered microfluidic channels for 3, 
6, 9, 12, 15, 18, and 21 days. Pericytes were seeded first on the reverse side of the porous 
polyester membranes with average pore size of 400 nm; b.End3 cells were then seeded 12 
hours onto the fibronectin coated side of the same membrane under normal culture 
conditions. The culture medium was removed from the apical (top) and basolateral (bottom) 
compartments before washing the b.End3 monolayers twice with PBS solution prior to 
starting the transport study. PBS solution in the apical compartment was replaced with 
marker solution before incubating in the microfluidic devices at 37 °C, 95% relative 
humidity, and 5% CO2 while shaking at transwells and layered microfluidic devices were 
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then placed on an orbital shaker spinning at 100 rpm inside an incubator under normal 
culture conditions for 60 minutes.  
The PBS solution in the receiver compartment in layered microfluidic channels and 
transwells were collected and replaced with fresh PBS every 10 minutes. At the end of the 
1 hour incubation time, PBS solutions in both the donor and receiver compartments were 
collected. All the collected PBS solutions were mixed with liquid scintillation fluid (GMI 
Inc., Ramsey, MN) and assayed using a liquid scintillation counter (GMI Inc., Ramsey, MN) 
to determine the concentration of each marker using a standard calibration curve.  
The permeability of a given molecule across the monolayer was calculated by using 
a derived form of a differential equation based on Fick’s Law: 
ܲ ൌ 	௏್ೌೞ೚೗ೌ೟೐ೝೌ೗	ൈ	
∆಴್ೌೞ೚೗ೌ೟೐ೝೌ೗
∆೟
஺	ൈ	஼ೌ೛೔೎ೌ೗  ------------------------------------------------------------- Equation 1 
Note that the transfer of solutes from the apical to the basolateral side is not concentration 
dependent, and only varies as a function of time.  The unit of measurement cm/s for 
permeability coefficient is commonly used. 
 
5.2.7 Assessment of Functional P-glycoprotein in b.End3 Cell Monolayers 
Functional expression of P-glycoprotein (P-gp) efflux pump by b.End3 and pericyte 
cells cultured in layered microfluidic channels was investigated by measuring the apical-to-
basolateral (AB) permeability and basolateral-to-apical (BA) permeability of [3H]-
Dexamethasone, which is a substrate for the P-gp efflux pump. Before starting the transport 
experiment, the culture medium in the apical and basolateral compartments in the 
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transwells and channels were replaced with fresh PBS at 37 °C for washing twice the cell 
monolayer. PBS solutions were then aspirated and replaced by [3H]-Dexamethasone at the 
apical (top) compartment for half of the total number of channels and transwells. The other 
half of channels and transwells were filled at the basolateral (bottom) compartment with the 
radioactively labeled marker. All other experimental conditions and solution retrieval 
procedures are the same as the paracellular permeability.  
In addition to the apical-to-basolateral permeability, basolateral-to-apical 
permeability was also evaluated by putting the radioactively labeled solution in the bottom 
compartment, and collecting the PBS solutions from the top compartment. Efflux ratio was 
calculated by using basolateral-to-apical permeability divided by the apical-to-basolateral 
permeability. If P-glycoprotein functionality was present, the efflux ratio should be higher 
than 1. 
 
5.3 RESULTS 
5.3.1 Endothelial Cell Viability and Morphology 
The design of our microfluidic device incorporates two layered microfluidic 
channels that sandwich a polyester membrane (0.4µm pore size) along the entire length of 
the channel, which was used to culture b.End3 cells in the top compartment. For bi-culture 
experiments where b.End3 cells and pericytes were used, pericytes were cultured on the 
back-side of the porous membrane in order to allow endothelial-pericyte contact to enhance 
barrier properties; for tri-culture experiments, an additional cell type - astrocytes were 
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Figure 5.1: (A) The schematic drawing of layered PDMS channel configuration with 
fluorescent images of b.End3, pericyte and astrocyte cells cultured in these channels (40mm 
x 2mm x 0.2mm) sandwiching polyester membrane filter (400 nm pore size). (B) b.End3, 
pericytes, and astrocytes stained with Live/Dead assay (Live/Dead Viability/Cytotoxicity 
Kit for mammalian cells, Invitrogen, Carlsbad, California) at different culture time points at 
10X magnification. 
 
Fluorescent images demonstrate the feasibility of culturing b.End3 cells with 
pericytes and astrocytes in layered configurations and formation of stable 3D cell layers for 
21 days (Figure 5.2A). Our results show that the number of viable b.End3 cells 
significantly increased from 499 cells/mm2 after 3 days in culture to 627 cells/mm2 after 6 
days and remained constant up to 21 days; while pericytes increased steadily from 295 
cells/mm2 after 3 days in culture to 444 cells/mm2 after 21 days for the bi-culture 
configuration and astrocytes also increased from 283 cells/mm2 after 3 days in culture to 
369 cells/mm2 after 21 days for the tri-culture configuration. These cell numbers after 6 
days indicate stable culture configurations for both of our bi-culture and tri-culture systems. 
We measured the angle (θ) between the spindle of b.End3 cells and the longitudinal 
axis of the microfluidic channels as a function of days in culture for both the bi- and tri-
culture systems. Fluorescent images of b.End3 cells show a 42°-43° angle between b.End3 
cells and the longitudinal axis of the microfluidic channels after 3 days in culture, which 
indicates a random organization of the cultured cells at early time points for both the bi- 
and tri-culture configurations (Figure 5.2B). However, this angle gradually decreased as a 
function of culture time reaching 25° and 21° after 21 days for the bi- and tri-culture 
configurations, respectively, which indicates gradual alignment of b.End3 cells along the 
length of the microfluidic channel. There is no significant difference of angle alignment 
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5.3.2 TEER of b.End3 Single Culture, b.End3-Pericyte Bi-Culture, and b.End3-
Pericyte-Astrocyte Tri-Culture 
TEER values were measured using embedded Ag/AgCl electrodes in both the top 
and bottom PDMS layers of the microfluidic channels (Figure 5.3A) [12]. TEER values 
were resolved by modeling the internal resistance of a cell and the capacitance of the cell 
membrane in series. Baseline TEER measurements across porous polyester membranes 
without seeding b.End3 cells were similar in layered microfluidic devices and transwells at 
different days in culture, which indicates that the layout of the device and composition of 
the culture medium (e.g. FBS serum) did not affect the calculated TEER values. 
Our results indicate that TEER across b.End3 single culture in microfluidic channels 
gradually increased from 28 Ohms.cm2 after seeding to 84, 125, and 143 Ohms.cm2 on days 
1, 2, and 3, respectively (Figure 5.3B). The b.End3 monolayers established in microfluidic 
channels maintained an average TEER of ~140 Ohms.cm2 between days 3 and 21 in culture. 
In comparison, b.End3-pericyte bi-culture configuration exhibited similar TEER value 
directly after seeding at 26 Ohms.cm2 and gradually increased to 257 Ohms.cm2 after 3 
days in culture and maintained similar values through 21 days. Bi-culture TEER values 
were 1.8-fold higher than that of the single culture which indicates viability and higher 
integrity of the formed barrier throughout the culture time (Figure 5.3B). Similarly, 
b.End3-pericyte-astrocyte tri-culture configuration exhibited similar values directly after 
seeding; however, after 3 days in culture, it increased even further and averaged to ~300 
Ohms.cm2, 1.2-fold higher than the bi-culture configuration. Our results indicate that 
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culture with pericytes and astrocytes in layered microfluidic devices as a function of time 
points (days). (*: p<0.05; **: p<0.01; ***: p<0.005); (+: p<0.05; ++: p<0.01; +++: p<0.005) 
 
5.3.3 Assessment of Paracellular Permeability Across b.End3 Cell Monolayers 
We investigated the transport of standard paracellular permeability markers [14C]-
mannitol and [14C]-urea across b.End3 cell monolayers cultured in layered microfluidic 
channels with bi- and tri-culture configurations. Our results show that permeability of 
[14C]-mannitol across b.End3 cell monolayers cultured in the bi-culture configuration was 
1.0 x 10-6 cm/s at day 3 and day 6, it decreased by 2-fold to 0.5 x 10-6 cm/s after 9 days in 
culture and remained constant for the rest of the 21-day culture period (Figure 5.4A). 
Permeability of [14C]-mannitol across b.End3 cell monolayers cultured in the tri-culture 
configuration demonstrated even lower permeability. At day 3 and day 6, the permeability 
is measured at ~0.6 x 10-6 cm/s and it decreased further to ~0.3 x 10-6 cm/s after 9 days in 
culture and remained constant for up to 21 days (Figure 5.4A). For b.End3 single culture in 
the microfluidic device, the permeability value was measured at 31.8 x 10-6 cm/s; it 
gradually decreased with increase in culture time to 13.8 x 10-6 cm/s at day 6 and ~3 x 10-6 
cm/s after 9 days in culture (Figure 5.4A). The 6-fold decrease of [14C]-mannitol 
permeability from single culture to bi-culture indicates that pericytes play a critical role in 
the formation and development of “restrictive” transport properties in our microfluidic 
device. Further decrease of permeability values from bi-culture to tri-culture (1.7-fold) 
indicates that astrocytes also play an important role in the formation of a “restrictive” 
barrier. 
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Results show similar trends in permeability of [14C]-urea across bi- and tri-culture 
configurations. After 3 days in culture, the permeability was measured at 1.4 x 10-6 cm/s 
and 1.2 x 10-6 cm/s; and 1.6 x 10-6 cm/s and 1.4 x 10-6 cm/s after 6 days, respectively 
(Figure 5.4B). However, after 9 days in culture, the permeability decreased to 1.1 x 10-6 
cm/s and 1 x 10-6 cm/s for the bi- and tri-culture, respectively, and stayed constant through 
the 21-day culture (Figure 5.4B). The permeability profiles of [14C]-mannitol and [14C]-
urea across the bi- and tri-culture systems indicate the development of a stable and 
“restrictive” barrier after 9 days in culture and both pericytes and astrocytes play important 
roles in its development. It is also important to note that both the bi- and tri-culture 
configurations can be maintained by 21 days and the difference between permeability of 
[14C]-mannitol and [14C]-urea with respect to the bi- and tri-culture configurations 
indicate a discrimination between small molecules. This size selectivity towards 
paracellular markers indicates the formation of tight junction complexes between adjacent 
endothelial cells in our systems, which is a key characteristic of the BBB in vivo [2, 7]. 
 
 
 
 
 
 
 
 
119 
(A) 
(B) 
 
 
 
 
 
 
Figure
conflu
with p
culture
parace
culture
microf
p<0.00
perme
culture
culture
 
5.3.4 
culture
barrier
model
calcula
 5.4: (A) C
ent bEnd3 m
ericyte and
 time points
llular perm
d with per
luidic devic
5) (C) Re
ability thro
d with per
 time points
Porosity of
The observ
 configurat
s and both
ing the inte
te the radiu
omparison 
onolayers w
 astrocyte c
 (days). (*: 
eability of 
icyte and tr
es as a func
nkin funct
ugh conflue
cityes and 
 (days). (*: 
 Bi- and Tri-
ed permeab
ions in mi
 pericytes a
rcellular sp
s (R) of the 
between par
ith single 
onditions i
p<0.05, **:
[14C]-urea 
i-cultured w
tion of cultu
ion calculat
nt bEnd3 
astrocytes in
p<0.05, **:
Culture Sys
ility of [14C
crofluidic c
nd astrocyt
ace betwee
pores of the
120 
(C) 
acellular pe
culture, bi-c
n layered m
 p<0.01, ***
through co
ith pericyte
re time poin
ion based 
monolayers
 layered m
 p<0.01, **
tems 
]-mannitol 
hannels ind
es play imp
n adjacent 
 tight junctio
rmeability o
ultured with
icrofluidic 
: p<0.005)
nfluent bEn
 and astroc
ts (days). (*
on [14C]-m
 bi-cultured
icrofluidic 
*: p<0.005)
and [14C]-u
icate the f
ortant role
endothelial
ns using th
 
f [14C]-ma
 pericyte, a
devices as 
 (B) Compa
d3 monola
yte conditio
: p<0.05, *
annitol an
 with peric
devices as 
 
rea across t
ormation o
s in its dev
 cells, we 
e Renkin fun
nnitol throu
nd tri-cultur
a function 
rison betwe
yers with b
ns in layer
*: p<0.01, *
d [14C]-ur
ytes and t
a function 
he bi- and t
f “restrictiv
elopment. B
were able 
ction: 
gh 
ed 
of 
en 
i-
ed 
**: 
ea 
ri-
of 
ri-
e” 
y 
to 
121 
ܨ ቀ௥ோቁ ൌ ሺ1 െ
௥
ோሻଶሾ1 െ 2.104 ቀ
௥
ோቁ ൅ 2.09 ቀ
௥
ோቁ
ଷ െ 0.95 ቀ௥ோቁ
ହሿ --------------------- Equation 2 
Where the Renkin function F( ௥ோ ) describes the relationship between the radius of the 
molecule (r) and the pore radius of the tight junction (R). 
The following equation provides a relationship between the permeability (P) and the 
Renkin function. 
ܲ ൌ ఢ஽ிሺ
ೝ
ೃሻ
ఋ  -------------------------------------------------------------------------------- Equation 3 
where ߳  is the porosity of the b.End3 monolayer, D is the diffusion coefficient of the 
evaluated marker molecule, and ߜ is the distance traversed by the marker molecule down a 
concentration gradient. We used the diffusion coefficients (D) of mannitol (9.65 x 10-6 
cm/s) and urea (13.8 x 10-6 cm/s) with our permeability results to solve the equation for the 
Renkin function and ఢఋ at different days in culture. We used Matlab R2009a to solve the 
polynomial equation and obtained R assuming that the radii (r) of mannitol and urea are 
0.34nm [19] and 0.26nm [19, 20], respectively. 
Our calculations show that the average radius of the tight junction pores (R) for the 
bi-culture configuration drops from 7.1nm and 7.9nm at day 3 and day 6, respectively, to 
2.1nm at day 9 and is maintained constantly until day 21. In comparison, the calculated 
radius of the tight junction pores (R) for the tri-culture configuration drops from 2.4nm at 
day 3 to 2.1nm at day 6, it drops even further to 1.6nm at day 9 and is maintained until day 
15 in culture. At day 18 and day 21, our data shows that the radius of the tight junction pore 
(R) decreases even further to 1.2nm (Figure 5.4C). The lower porosity established in the 
tri-culture configuration compared to the bi-culture reinforces the idea that astrocytes play a 
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significant role in the development of “restrictive” tight junctions in the b.End3 cell layer. 
Since the astrocytes were seeded at the bottom layer of the channels and had no direct 
contact with the b.End3-pericyte layers, it can be concluded that astrocytes act through the 
secretion of neurotrophic factors that have the ability to influence barrier formation at the 
BBB [2, 5, 6]. 
 
5.3.5 Effect of Bottom Channel Height on Barrier Properties of the Tri-Culture 
Configuration 
Based on our permeability data and calculations of the radius (R) of tight junction 
pores, we concluded that astrocytes act on the barrier properties through secreted 
neurotrophic factors. It has shown that with astrocytes in the system, the permeability of 
both [14C]-mannitol and [14C]-urea were lowered which indicates more “restrictive” tight 
junction formation; the TEER values were increased which indicates “tighter” barrier. 
Therefore, we hypothesized that by controlling the height of the bottom channel where the 
astrocytes are seeded and grown, it will affect the barrier properties of the b.End3 cells 
growing in the top channel through TEER measurements and permeability. To further 
validate the role of the astrocytes, we fabricated layered microfluidic channels that are 
0.6mm and 1mm high in the bottom channel while keeping the top channel dimensions the 
same.  
Our results show that increasing the bottom channel’s height to 0.6mm decreased 
the TEER measurements by ~20 Ohms.cm2 after 3 days in culture. Increasing the height to 
1mm decreased the TEER measurements even further by another ~20 Ohms.cm2 after 3 
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days (Figure 5.5A). The incremental decline in TEER measurements that we observed with 
our tri-culture configuration using different height for the bottom channel where astrocytes 
are cultured show that distance between the astrocytes and b.End3 cells make a difference 
in the development of endothelial barrier properties despite identical seeding density and 
culture conditions. This effect demonstrates that by increasing the distance needed for the 
neurotrophic factors to traverse and increasing the overall volume of the bottom channel 
resulting in dilution of these factors, we are able to manipulate the barrier properties of the 
b.End3 layers. 
We also investigated the permeability of [14C]-mannitol across the bi- and tri-
culture configurations with modified height of 0.6mm and 1mm for the bottom channels. 
Specifically our data shows that with 1mm height for the bottom channel, the permeability 
of [14C]-mannitol in the tri-culture configuration with astrocytes shows little difference 
from the bi-culture configuration without astrocytes. This indicates that at a large distance 
and channel volume, the astrocytes are ineffective at promoting the formation of 
“restrictive” tight junctions. With 0.6mm height for the bottom channel, the permeability of 
[14C]-mannitol decreased from ~0.53 x 10-6 cm/s to ~0.43 x 10-6 cm/s at day 9, 12, 15, 18, 
and 21 days in culture (Figure 5.5B). When we compare 0.6mm height channels with 
0.2mm height channels, we found that the permeability of [14C]-mannitol decreased even 
further to 0.3 x 10-6 cm/s at the end of 21-day culture. Similar to the TEER measurements, 
we found incremental decline in the permeability of [14C]-mannitol which further confirms 
that distance between the astrocytes and b.End3 cells and dilution of these neurotrophic 
factors play a critical role in the effectiveness of the astrocytes in affecting the barrier 
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paracellular permeability of [14C]-mannitol through confluent bEnd3 monolayers with tri-
culture configuration in layered microfluidic devices with modified height of the bottom 
channel at 0.2mm, 0.6mm, and 1mm as a function of time points (days). (*: p<0.05; **: 
p<0.01; ***: p<0.005); (+: p<0.05; ++: p<0.01; +++: p<0.005) 
 
5.3.6 Functional Expression of P-glycoprotein by the Bi- and Tri-Culture Systems 
We measured the apical-to-basolateral (AB) and basoalteral-to-apical (BA) 
permeability of [3H]-Dexamethasone, which is a substrate for the P-gp efflux pump across 
the bi- and tri-culture configurations with regular 0.2mm height at the bottom channels. 
Functional expression of the P-gp on the apical side of b.End3 cells would decrease the AB 
permeability of dexamethasone and increase the BA permeability. Therefore, we calculated 
the Efflux Ratio (ER) across b.End3 cell layers using the following equation. 
ܧܴ ൌ 	 ௉௘௥௠௘௔௕௜௟௜௧௬ಳಲ௉௘௥௠௘௔௕௜௟௜௧௬ಲಳ -------------------------------------------------------------------- Equation 4 
  Results show that both bi- and tri-culture configurations exhibit high BA 
permeability of [3H]-dexamethasone relative to its respective AB permeability (Figure 
5.6A). For the bi-culture configuration, the Efflux Ratio was 1.2 at day 3 and gradually 
increased to 2.5 at the end of the 21-day culture period. For the tri-culture configuration, the 
Efflux Ratio was 1.6 at day 3 and gradually increased to 4.8 at the end of 21-day (Figure 
5.6B). The data indicates that both the bi- and tri-culture configurations are capable of 
inducing the functionality of P-gp pumps; however, as a function of days in culture, the tri-
culture configuration is significantly more effective at inducing P-gp activities which is 
another key characteristic of the BBB. 
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Previous researches have suggested that pericytes, based on their morphology and 
localization, play important roles in endothelial cell function and modulation of blood flow, 
and they make direct contact with endothelial cells through gap and adherens junctions [22, 
24, 25]. It is also important to note that at the BBB the ratio of pericytes to endothelial is 
one of the highest in any organ [26]. Furthermore, there are evidences in the literature that 
suggest pericytes are capable of secreting signaling molecules that are essential to the 
differentiation and contractile properties of endothelial cells [27-29]. Astrocytes, too, have 
been found to secrete a range of neurotrophic factors such as transforming growth factor-β 
(TGFβ) [5], glial-derived neurotrophic factor (GDNF) [30], and basic fibroblast growth 
factor (bFGF) [5]. It has been found that these factors can induce many aspects of the BBB 
phenotype in endothelial cells in vitro [2, 5, 7]. At the same time, endothelial-derived factor 
such as leukaemia inhibitory factor (LIF) has been documented to induce the differentiation 
of astrocytes [31]. The cross-interaction between endothelial cells and astrocytes are 
mutually beneficial and ensures the differentiation of both BBB and astrocytic development. 
Based on the importance of pericytes and astrocytes on endothelial differentiation, 
we designed our bi- and tri-culture configurations to examine the feasibility of culturing 
b.End3 cells together with pericytes and astrocytes and whether these co-culture 
configurations can induce BBB-like transport properties. For our bi-culture configuration, 
our goal was to mimic the close promixity of endothelial cells and the pericytes; therefore 
we cultured pericytes on the back-side of the semi-porous membrane, where the endothelial 
cells were growing on, in the microfluidic devices. This configuration ensures that b.End3 
cells and pericytes are in close contact with each other in the condition that is similar to the 
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conditions in vivo. Our results demonstrated that pericytes can in fact improve the barrier 
properties of b.End3 layers through TEER measurements, permeability of paracellular 
markers such as mannitol and urea, and porosity calculations. For our tri-culture 
configuration, we added astrocytes to the bottom layer of the channels. While the astrocytes 
are not in direct contact with the endothelial-pericyte layers, the secreted neurotrophic 
factors that are so critical to the BBB development still reaches the b.End3 cells through 
diffusion; again, creating a similar condition to the in vivo conditions. Our results of the tri-
culture configuration show even further enhancement of the barrier properties compared to 
the bi-culture configuration. It is worth mentioning that when we compare our [14C]-
mannitol permeability value at the end of 21 days in culture, which is 0.3 x 10-6 cm/s, it is 
very close to the in vivo permeability value of 0.2 x 10-6 cm/s [2, 32]. Similarly, our 
porosity calculations show the lowest tight junction radius in our tri-culture configuration 
to be 1.2nm, where the in vivo value is measured to be 0.8nm [33]. Our results indicate that 
by culturing b.End3 cells together with pericytes and astrocytes according to the tri-culture 
configuration in microfluidic devices can induce BBB transport properties very similar to 
the in vivo data. 
To further validate the effects of astrocytes on endothelial-pericyte layers, we 
modified our original device and changed the height of the bottom channel from 0.2mm to 
0.6mm and 1mm. The purpose of modifying the bottom channel is to increase the distance 
between the astrocytes and the endothelial-pericyte layers and increase the volume of the 
bottom channel in order to subject the secreted neurotrophic factors to dilution. Through 
TEER measurements and permeability values, we were able to clearly demonstrate that 
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when astrocytes are far apart from the endothelial-pericyte layers, in this instance 1mm, 
astrocytes have little effect on the barrier properties of b.End3 cells. This conclusion is 
based on the fact that [14C]-mannitol permeability shows no statistical difference between 
the bi-culture configuration and the tri-culture configuration utilizing 1mm height in the 
bottom channel. The incremental decline of TEER measurements from using 0.2mm 
channel to 0.6mm channel to 1mm channel also demonstrates that as astrocytes are 
removed farther and farther away from the endothelial-pericyte layers, its effect is 
diminished as a function of bottom channel height. These results clearly indicate that close 
proximity of astrocytes with the endothelial-pericyte layers is required to induce proper 
BBB characteristics within the microfluidic devices. 
Finally, we demonstrated the ability of the bi- and tri-culture configurations to 
induce P-gp pumps by measuring the AB and BA permeability using [3H]-dexmathasone. 
The calculated Efflux Ratio based on permeability shows highly functional P-gp by 
cultured cells starting on day 15 and is maintained until day 21. 
 
5.5 CONCLUSION 
  We report the successful culture of brain endothelial cells (b.End3) with pericytes in 
a bi-culture configuration and astrocytes with b.End3-pericyte layers in a tri-culture 
configuration forming a viable 3D model of the blood-brain barrier that exhibits restrictive 
transport properties indicated by high TEER values and low [14C]-mannitol and [14C]-urea 
permeability. In addition, these bi- and tri-culture configurations exhibited high P-gp 
functionality through the calculation of Efflux Ratio. All of the results lead us to believe 
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that we have created an accurate model of the BBB in vitro that can be utilized for drug 
screening and research purposes. 
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Chapter 6 
 
Conclusion and Future Works 
 
 
This research project successfully built an in vitro model of the blood-brain barrier 
that is capable of mimicking its physiological properties in vivo. Through vigorous 
verifications, we confirmed that PDMS that is required for building flexible and cell culture 
friendly channels have a limit to its quantitative assay applications. We found that 
hydrophobic molecules having log P values larger than 2.47 will induce hydrophobic 
interactions with PDMS channel walls, thus making quantitative assays inaccurate. 
However, any molecular markers with less hydrophobicity can be safely used in 
microfluidic PDMS channels. Next, we designed and built our microfluidic PDMS 
channels in such a way that it allows both 3D cell culture configurations and quantitative 
assays. We initially verified the cell culture aspect of the device by culturing bEnd3 single 
culture monolayers. We found that by culturing bEnd3 cells inside the device, we not only 
were able to increase the longevity of the cell culture, we also found higher TEER values, 
lower paracellular permeability, and higher P-gp functionality when compared to 
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conventional transwells. Finally, we added pericytes to complete the bi-culture 
configuration and astrocytes to complete the tri-culture configuration. Both of these 
configurations showed closer mimicry of the BBB than the single culture, confirming the 
importance of both of these cell types in the development and proliferation of the BBB. 
Furthermore, we found that our tri-culture configuration exhibited similar paracellular 
permeability as the in vivo data collected by other research groups, and the radius of tight 
junctions is also close to the in vivo values through the use of mathematical modeling. We 
believe that the device in its current state can accurately model the BBB and has the 
potential to allow us to better understand the mechanisms involved in regulating barrier 
properties of single and co-culture endothelial cell monolayers, provide a tool to accurately 
evaluate the permeability of new drug candidates across the BBB, and allow accurate in 
vitro/in vivo correlation of drug transport profiles, which will accelerate the development of 
new therapies for treatment of CNS disorders. 
Currently, the 3D configuration produces the most accurate results; however, it 
requires constant supervision and medium changes of four times a day. The constant energy 
required for upkeep of these channels is potentially an issue and was somewhat problematic 
even during the experimental stage. The immediate future work is to rectify this issue by 
implementing automated medium change into the system in such a way that medium can be 
changed automatically on a daily basis with minimal human intervention. This can be 
achieved by implementing a braille system into the device or adding an additional pump to 
the device. Once this is complete, we can culture a large array of channels simultaneously 
with minimal effort, which seems to be a requirement for this device to become a 
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commercially successful product. Furthermore, we are planning to develop a pathological 
model of the BBB to model the diseased condition by altering either the 3D composition or 
culture conditions for the cells, such as oxygen level and seeding density. We believe that if 
a pathological model can be developed, it will further assist us in understanding the BBB in 
diseased conditions and accelerating the process of drug discovery. 
